

24.03.2021

12:00 - 20:00 **e-Poster Display Session**

ePoster Display

12:00 - 12:00 **Tumour biology and pathology**

12:00 - 12:00 **1P - Real-world Frequency of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (Exon20ins) Mutations by Site of Insertion**

S. Viteri¹, J. Bauml², L. Bazhenova³, S.-H.I. Ou⁴, N. Girard⁵, M. Schaffer⁶, J. Rose⁶, J. Curtin⁶, J. Karkera⁶, P. Mahadevia⁷, A. Minchom⁸, ¹Dr Rosell Oncology Institute, Dexeus University Hospital, QuironSalud Group, Barcelona, ES, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, US, ³Moore's Cancer Center - UC San Diego Health, La Jolla, US, ⁴University of California Irvine, Orange, US, ⁵Institut Curie, Paris, FR, ⁶Janssen R&D, Spring House, US, ⁷Janssen Pharmaceuticals, Raritan, US, ⁸The Royal Marsden Hospital - NHS Foundation Trust, London, GB

12:00 - 12:00 **2P - Role of neutrophil-to-lymphocyte ratio (NLR) in the outcome of NSCLC EGFR mutated**

S. Tolu¹, G. Saba², V. Impera¹, D. Spanu², N. Liscia¹, G. Pinna², A. Pireddu¹, L. Demurtas², E. Lai², F. Manca², C. Madeddu², E. Massa³, G. Astara², M. Scartozzi², ¹University of Cagliari - Sapienza Università di Roma, Monserrato (CA), IT, ²University of Cagliari, Monserrato (CA), IT, ³ Monserrato, IT

12:00 - 12:00 **3P - AZ12756122, a novel Fatty Acid Synthase (FASN) inhibitor, reduces resistance properties in Gefitinib- and Osimertinib resistant EGFR-mutated non-small cell lung cancer models**

E. Polonio-Alcalá¹, S. Palomeras¹, R. Porta-Balanya², J. Bosch-Barrera², C. Vázquez³, J. Ciurana¹, S. Ruiz-Martínez¹, T. Puig¹, ¹University of Girona, Girona, ES, ²ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, ³Institut Català de la Salut, Girona, ES

12:00 - 12:00 **4P - Prevalence of MET Exon 14-mutations or MET amplification in non-small cell lung cancer in Swiss patients**

S. Savic Prince¹, M. Bihl¹, S. Eppenberger-Castori¹, M.S. Matter¹, N. Zellweger¹, S. Rothschild¹, L. Bubendorf², ¹University Hospital Basel, Basel, CH, ²University Hospital Basel - Institute of Pathology, Basel, CH

12:00 - 12:00 **5P - False positives errors in RNA based next generation sequencing of exon 14 skipping mutations in NSCLC**

M. Suryavanshi¹, S. Mattoo², U. Batra³, S. Sharma¹, D. Kumar⁴, A. Mehta¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Center, Delhi, IN, ³Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN, ⁴Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN

12:00 - 12:00 **6P - Clinical and molecular characteristics in non-small cell lung cancer patients with alteration in PIK3 pathway.**

Y. Lage, P. Alvarez Ballesteros, M.E. Olmedo García, A. Gómez Rueda, E. Corral De La Fuente, J. Torres Jimenez, E. Vida Navas, J.J. Soto Castillo, M. Lario, A. Benito Berlinches, A. Santón, P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

- 12:00 - 12:00 **7P - STK11 and Galectin-3 Tissue Expression Entails a Prognostic Signature in Immunotherapy Treated NSCLC patients**
G. Mazzaschi¹, R. Minari¹, L. Gnetti², N. Campanini², T. Zielli³, M. Baucina¹, F. Perrone², A. Leonetti², F. Quaini², M. Tiseo⁴, ¹University Hospital of Parma, Parma, IT, ²Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ³AOU di Parma, Parma, IT, ⁴Department of Medicine and Surgery, University of Parma, Parma, IT
- 12:00 - 12:00 **8P - Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules**
Y. Ma, M. Qiu, Peking University People's Hospital, Beijing, CN
- 12:00 - 12:00 **9P - Lung cancer mutational state assessed by NGS in a Portuguese Center**
D. Magalhães¹, M. Vilaça¹, É. Cipriano¹, A. Tavares¹, D. Silva¹, L. Cirnes², H. Magalhães¹, F. Estevinho¹, ¹ULS Matosinhos - Hospital Pedro Hispano EPE - SNS, Senhora da Hora, PT, ²Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, PT
- 12:00 - 12:00 **10P - Impact of the number of metastatic lymph nodes on survival in pathological stage II-N1 non-small cell lung cancer**
J. De Ruiter¹, A. De Langen¹, K. Monkhorst¹, A. Veenhof¹, H. Klomp¹, R. Damhuis², K. Hartemink¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Netherlands Comprehensive Cancer Organisation, Utrecht, NL
- 12:00 - 12:00 **11P - LINC00926 is a B cell-specific long noncoding RNA in lung adenocarcinoma and is associated with the prognosis of patients with this disease**
J. Li¹, H. Guo², Y. Ma¹, H. Chen¹, M. Qiu¹, ¹Peking University People's Hospital, Beijing, CN, ²Beijing Chest Hospital, Beijing, CN
- 12:00 - 12:00 **Translational research**
- 12:00 - 12:00 **12P - Clonal evolution in lung cancer highlights MCL-1 gains as therapeutic target in lung adenocarcinoma**
P. Jost¹, E. Munkhbaatar², M. Dietzen³, C. Branca², N. Mcgranahan⁴, ¹Medical University of Graz, Graz, AT, ²Technical University of Munich, München, DE, ³UCL - University College London, London, GB, ⁴UCL Cancer Institute - Paul O'Gorman Building, London, GB
- 12:00 - 12:00 **13P - M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma**
H. Zhu¹, M. Liu¹, B. Xu², H. Chen², H. Cheng², K. Zhao¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²The First Affiliated Hospital of Nanjing Medical

University, Nanjing, CN

- 12:00 - 12:00 **14P - Studying tumour heterogeneity of primary non-small cell lung cancer in humans and mice (PDX)**
Z. Kanaki¹, A. Voutsina¹, A. Markou², A. Markou³, I. Samaras³, I. Pateras⁴, E. Baliou⁴, E. Patsea⁵, K. Potaris⁶, K. Vahlas⁶, L. Toufektzian⁶, I. Vamvakaris⁶, P. Makrythanasis¹, V. Georgoulas⁴, A. Kotsakis⁷, A. Klinakis¹, ¹Biomedical Research Foundation, Academy of Athens, Athens, GR, ²University of Athens, Athens, GR, ³University Hospital of Larissa, Larissa, GR, ⁴Hellenic Oncology Research Group (HORG), Athens, GR, ⁵Metropolitan General Hospital, Athens, GR, ⁶SOTIRIA General Hospital of Athens, Athens, GR, ⁷Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, GR
- 12:00 - 12:00 **15P - The genomic landscape of pleomorphic lung cancer using whole exome sequencing**
L. Roma¹, C. Ercan¹, F. Conticelli², S. Piscuoglio³, C. Ky Ng⁴, L. Bubendorf¹, ¹University Hospital Basel - Institute of Pathology, Basel, CH, ²University of Naples "Federico II", Naples, IT, ³University Hospital Basel - Institute of Pathology and Medical Genetics, Basel, CH, ⁴University of Bern, Bern, CH
- 12:00 - 12:00 **16P - Prognostic Role of Circulating MicroRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer**
A. Monastirioti¹, C. Papadaki¹, K. Rounis², D. Kalapanida², D. Mavroudis², S. Agelaki², ¹University of Crete, Heraklion, GR, ²University Hospital of Heraklion (PAGNI), Heraklion, GR
- 12:00 - 12:00 **17P - The value of Th2-related thymic stromal lymphopoietin as a prognostic and predictive biomarker in non-small cell lung cancer**
M. Cavic, V. Jokic, M. Marinkovic, N. Stanic, R. Jankovic, D. Radosavljevic, J. Spasic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
- 12:00 - 12:00 **18P - Gene expression-based identification of prognostic markers in lung adenocarcinoma**
A. Salomonsson¹, M. Jönsson¹, H. Brunnström¹, J. Staaf¹, M. Planck², ¹Lund University, Lund, SE, ²Dept. of Pulmonary medicine, Skåne University Hospital, Lund, SE
- 12:00 - 12:00 **19P - A synergistic combination therapy for KRAS-driven cancers**
Z. Yang¹, S.-Q. Liang², R.-W. Peng², R. Schmid², ¹Inselspital, Bern University Hospital, University of Bern, Bern, CH, ²Division of General Thoracic Surgery, Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, CH
- 12:00 - 12:00 **20P - Synergistic inhibition of growth of KRAS-driven NSCLC by MEK inhibitor in combination with a novel multi-target tyrosine kinase inhibitor anlotinib via IGF1R-mediated signaling**
M. Hu, J. Lu, B. Han, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00

Last update: 24-03-2021 11:06:48am

21P - The landscape of ALK alterations in Non-Small Cell Lung Cancer

A. Desai¹, T. Mohammed², S. Rakshit³, J. Krull³, ¹MayoClinic, Rochester, US, ²University of Connecticut, Hartford, US, ³Mayo Clinic, Rochester, US

12:00 - 12:00 **22P - Clinical utility of ddPCR for detection of sensitizing and resistance EGFRm in pts with advanced NSCLC**

M. Riudavets Melià¹, V. Lamberts², E. Auclin³, M. Aldea⁴, D. Vasseur⁴, C. Jovelet², C. Naltet², P. Lavaud², A. Gazzah², F. Aboubakar², E. Rouleau², J. Remon², L. Lacroix², M. Ngocamus², C. Nicotra², B. Besse², D. Planchard², L. Mezquita⁵, ¹Gustave Roussy cancer campus, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Hôpital Européen Georges Pompidou, Paris, FR, ⁴Institute Gustave Roussy, Villejuif, FR, ⁵Hospital Clinic i Provincial de Barcelona, Barcelona, ES

12:00 - 12:00 **23P - Clinical utility of cell free DNA in pleural lavage and plasma in resectable NSCLC- A pilot study**

J. Saikia, P. Malik, D. Jain, S. Kumar, S. Bharati, K. Madan, P. Gamit, S.V.S. Deo, S. Kumar, All India Institute of Medical Sciences, New Delhi, New Delhi, IN

12:00 - 12:00 **24P - Peripheral blood transcriptomics reveal novel resistance mechanisms in immune checkpoint inhibitor (ICI) treated non-small cell lung cancer (NSCLC) patients**

J. Mankor¹, H. Vroman¹, R. Stadhouders¹, A.-M. Dingemans², J. Aerts¹, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus MC - University Medical Center, Rotterdam, NL

12:00 - 12:00 **25P - Evaluation of PD-L1 and Ki67 markers in CTCs of NSCLC patients treated with Pembrolizumab**

M. Spiliotaki¹, H. Charalambous², C. Neophytou³, G. Gregoriou¹, P. Vogazianos⁴, C. Deltas¹, A. Constantinou¹, ¹University of Cyprus, Nicosia, CY, ²Bank of Cyprus Oncology Centre, Nicosia, CY, ³University of Cyprus, NICOSIA, CY, ⁴European University of Cyprus, Nicosia, CY

12:00 - 12:00 **26P - Analysis of prognostic and predictive factors of response in squamous cell carcinoma using NGS techniques**

P. Cruz Castellanos¹, L. Gutiérrez Sainz¹, O. Higuera Gomez¹, C. Antolin¹, R. Rosas Alonso¹, I. Ibañez¹, B. Castelo¹, X. Mielgo Rubio², J. De Castro Carpeno¹, ¹Hospital Universitario La Paz, Madrid, ES, ²Hospital Universitario Fundación Alcorcón, Alcorcon, ES

12:00 - 12:00 **27P - The association between gut microbiome and response to checkpoint inhibitor therapy in non-small cell lung cancer**

H. Moon¹, J. Moon², ¹Yonsei University Medical Center, Seoul, KR, ²Sungju Moogang Hospital, Sungju, KR

12:00 - 12:00 **28P - Adherence to treatment recommendations from multidisciplinary tumor boards**

J. Roeper¹, L. Kathmann², A. Blanksma², L. Ansmann¹, F. Griesinger³, ¹University of

Oldenburg, Oldenburg, DE, ²Pius Hospital, Oldenburg, DE, ³Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE

- 12:00 - 12:00 **Prevention, Early detection, Epidemiology, Tobacco control**
- 12:00 - 12:00 **30P - Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008-2018: a nationwide population-based study from the Netherlands**
J. Evers¹, K. De Jaeger², L. Hendriks³, M. Van Der Sangen², C. Terhaard⁴, S. Siesling¹, D. De Ruyscher⁵, H. Struikmans⁶, M. Aarts¹, ¹Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, NL, ²Catharina Hospital, Eindhoven, NL, ³Maastricht University Medical Center (MUMC), Maastricht, NL, ⁴Utrecht University Medical Center, Utrecht, NL, ⁵Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, Maastricht, NL, ⁶Leiden University Medical Centre, Leiden, NL
- 12:00 - 12:00 **31P - Lung cancer survival in Sri Lanka**
L. Alagiyawanna¹, S. Wijesekera¹, V. Peiris¹, D. Silva¹, T. Rupasinghe¹, T. Skandarajah¹, N. Jeyakumar¹, D. Gunasekera¹, N. Joseph², ¹National Cancer Institute of Sri Lanka, Maharagama, LK, ²District General Hospital Chilaw, Chilaw, LK
- 12:00 - 12:00 **32P - Patient experience and outcomes during lung cancer treatment : a systematic review**
S. Hussain, The University of Birmingham - Medical School, Birmingham, GB
- 12:00 - 12:00 **33P - Demographic differentials of lung cancer survival in Bangladeshi patient**
M.R. Islam¹, A.T.M. Hasan¹, N. Khatun¹, I. Ridi¹, N. Ishrat¹, S. Das¹, F. Arjuman¹, H. Ahmed², F. Begum³, M. Islam¹, M. Rahman¹, M. Karim⁴, A. Hossain¹, M. Hossen¹, ¹NICRH - National Institute of Cancer Research & Hospital, Dhaka, BD, ²Bangabondhu Sheikh mujib Medical University, Dhaka, BD, ³Bangladesh Specialized Hospitals Limited, Dhaka, BD, ⁴Monash University, Melbourne, AU
- 12:00 - 12:00 **34P - Sex and age differences in primary lung cancer in Morocco: an epidemiologic study**
O. Erefai, A. Soulaymani, A. Mokhtari, H. Hami, Faculty of Science, Ibn Tofail University, Kenitra, MA
- 12:00 - 12:00 **35P - Lung cancer diagnosis and continuum of care: How did COVID 19 outbreak impact? Data from an Italian multicenter study**
L. Cantini¹, G. Mentrasti¹, N. La Verde², M.S. Cona², R. Chiari³, E. Martinelli⁴, F. Morgillo⁵, L. Nicolardi³, A. Cortellini⁶, V. Pensieri⁷, V. Cognigni¹, G. Pinterpe¹, T. Galassi¹, F. Pecci¹, P. Mazzanti¹, M. Di Pietro Paolo¹, R. Giampieri¹, R. Berardi⁸, ¹AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, ²ASST Fatebenefratelli Sacco, Milano, IT, ³Oncologia Ospedali Riuniti Padova Sud, Monselice, IT, ⁴Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁵Università degli studi della Campania Luigi Vanvitelli, Napoli, IT, ⁶Ospedale Civile San Salvatore, L'Aquila, IT, ⁷Ospedale Civile San Salvatore - ASL 1- Avezzano Sulmona L'Aquila,

L'Aquila, IT, ⁸Università Politecnica Marche, AOU Ospedali Riuniti, Ancona, IT

- 12:00 - 12:00 **36P - Cost-effectiveness of lung cancer screening with low-dose computed tomography in China: a modeling study**
Y. Du¹, Y. Li², G. Sidorenkov¹, Z. Ye², R. Vliegenthart¹, M. Heuvelmans¹, M. Dorrius¹, H. Groen¹, S. Liu³, L. Fan³, M. Greuter¹, G. De Bock¹, ¹UMCG - University Medical Center Groningen, Groningen, NL, ²Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ³Shanghai Changzheng Hospital, Shanghai, CN
- 12:00 - 12:00 **37P - Emerging usage of Low-dose Computed tomography scanning in lung cancer screening: A Single Vietnamese institutional assessment**
D. Trung Hiep, H. Nguyen, H. Nguyen, Vinmec Times City International Hospital, Hanoi, VN
- 12:00 - 12:00 **38P - Brain metastases in non-small cell lung cancer in era of molecularly driven therapy**
S. Rakshit¹, R. Bansal¹, A. Desai², K. Leventakos¹, ¹Mayo Clinic, Rochester, US, ²MayoClinic, Rochester, US
- 12:00 - 12:00 **39P - Tissue vs Cobas vs DDPCR for EGFR in NSCLC: Real world evidence from India**
U. Batra¹, M. Sharma¹, S. Nathany¹, H. Singh¹, P. Jain¹, A. Mehta², ¹Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
- 12:00 - 12:00 **40P - Revealing the Association Between Lung Cancer and Allergic Respiratory Diseases: Meta-analysis of Cohort Studies**
B.P. Putra¹, F.N. Putra², ¹Medical Doctor, Blitar, ID, ²Faculty of Medicine Universitas Airlangga, Surabaya, ID
- 12:00 - 12:00 **41P - Increased Lung Cancer Risk in Gastroesophageal Reflux Disease and Helicobacter pylori Infection Patients: Systematic Review and Meta-analysis**
B.P. Putra¹, F.N. Putra², ¹Medical Doctor, Blitar, ID, ²Faculty of Medicine Universitas Airlangga, Surabaya, ID
- 12:00 - 12:00 **Imaging and staging**
- 12:00 - 12:00 **42P - Radiation induced pneumonitis in the era of COVID-19 pandemic: artificial intelligence for differential diagnosis.**
S. Ramella¹, C. Quattrocchi¹, E. Ippolito¹, F. Giordano¹, C. Greco¹, C. Mallio¹, B. Santo¹, P. D'Alessio¹, M. Fiore¹, R. D'Angelillo², B. Beomonte Zobel¹, ¹Campus Bio-Medico University, Rome, IT, ²Tor Vergata University, Rome, IT
- 12:00 - 12:00 **43P - Incidentally discovered suspicious lung lesions in hospitalized patients during COVID-19 pandemic in Georgia**

M. Abuladze, K. Saganelidze, D. Barabadze, M. Kavtaria, New Vision University, Tbilisi, GE

12:00 - 12:00

44P - Inter-reader variability of lung parenchymal observations on Chest CT among COVID-19 RT-PCR negative lung cancer patients treated with chemo-radiation: Potential pitfalls of pulmonary findings in different readers with various experience levels

A. Jajodia¹, H. Prosch², U. Batra³, B. Amrith¹, J. Goyal¹, S. Pasricha¹, A. Mehta¹, D.C. Doval¹, S. Puri¹, A. Chaturvedi¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Medical University of Vienna, Austria, vienna, AT, ³Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN

12:00 - 12:00

45P - Analysis of lung cancer patient pathway: A 6-year nationwide analysis from Hungary

K. Bogos¹, G. Gaffly², Z. Kiss³, L. Tamási⁴, G. Ostoros¹, V. Müller⁴, L. Urbán⁵, N. Bittner⁶, V. Sárosi⁷, A. Vastag³, Z. Polányi³, A. Daniel³, B. Nagy⁸, G. Rokszin⁹, Z. Abonyi-Tóth⁹, Z. Barcza¹⁰, J. Moldvay², Z. Vokó¹¹, ¹National Korányi Institute of Pulmonology, Budapest, HU, ²Pulmonology Hospital Törökbálint, Törökbálint, HU, ³MSD Pharma Hungary Kft., Budapest, HU, ⁴Department of Pulmonology, Faculty of Medicine, Semmelweis University, Budapest, HU, ⁵6. Matraháza Healthcare Center and University Teaching Hospital, Mátraháza, HU, ⁶7. Pulmonology Clinic University of Debrecen, Debrecen, HU, ⁷8. Faculty of Medicine, University of Pécs, Pécs, HU, ⁸Eötvös Loránd University, Budapest, HU, ⁹RxTarget Ltd., Szolnok, HU, ¹⁰Syntesia Ltd., Budapest, HU, ¹¹Semmelweis University, Budapest, HU

12:00 - 12:00

46P - Comparison of 7th and 8th editions AJCC/UICC TNM staging in correlation with survival and treatment guidelines for non-small cell lung cancer

T. Irura, A. Ashour, O. Zahra, Alexandria clinical oncology department, Alexandria, EG

12:00 - 12:00

47P - Central Nervous-System (CNS) Metastases in Thymic Epithelial Tumors (TET): real-world insight from RYTHMIC

J. Benítez¹, M.-E. Boucher², E. Dansin³, M. Kerjouan⁴, L. Bigay-Game⁵, E. Pichon⁶, F. Thillays⁷, P. Falcoz⁸, S. Lyubimova⁹, Y. Oulkhour¹⁰, F. Calcagno¹¹, L. Thiberville¹², C. Clément-Duchêne¹³, V. Westeel¹⁴, P. Missy¹⁵, P.A. Thomas¹⁶, T. Molina¹⁷, N. Girard¹⁸, B. Besse¹⁹, ¹Gustave Roussy - Cancer Campus, Villejuif, Cedex, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Centre Oscar Lambret, Lille, FR, ⁴Centre Hospitalier Universitaire de Rennes, Rennes, FR, ⁵Centre Hospitalier Universitaire de Toulouse, Toulouse, FR, ⁶CHRU de Tours, Hôpital Bretonneau, Tours, FR, ⁷Institut de Cancérologie de l'ouest, Rouen, FR, ⁸Centre Hospitalier Universitaire de Strasbourg, Strasbourg, FR, ⁹Centre Hospitalier Universitaire de Montpellier, Montpellier, FR, ¹⁰Centre Hospitalier Universitaire de Caen, Caen, FR, ¹¹Centre Hospitalier Universitaire de Besançon, Besançon, FR, ¹²Hop. Charles Nicolle, Rouen, FR, ¹³Institut de Cancérologie de Lorraine, Nancy, FR, ¹⁴CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ¹⁵French Cooperative Thoracic Intergroup, Paris, FR, ¹⁶Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ¹⁷Hôpital Universitaire Necker Enfants Malades, Paris, FR, ¹⁸Institut Curie, Paris, FR, ¹⁹Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00

SCLC

- 12:00 - 12:00 **50P - A Phase 1b Study of CC-90011, a Potent, Reversible, Oral LSD1 Inhibitor, Plus Etoposide and Cisplatin (EP) or Carboplatin (EC) in Patients (Pts) With First-Line (1L) Extensive-Stage (ES) Small Cell Lung Cancer (SCLC): Updated Results**
- S. Ponce Aix¹, O. Juan-Vidal², E. Carcereny³, J. Trigo⁴, M. Provencio⁵, L. Greillier⁶, A. Navarro⁷, J. Bennouna⁸, A. Santoro⁹, R. Berardi¹⁰, B. Besse¹¹, H. Gonzalez¹², J. De Alvaro¹², J. Parra-Palau¹², T. Sánchez-Pérez¹², I. Aronchik¹³, E. Filvaroff¹³, M. Lamba¹³, Z. Nikolova¹², L. Paz-Ares¹⁴, ¹Hospital Universitario 12 de Octubre, Universidad Complutense and Ciberonc, Madrid, ES, ²Hospital Universitari I Politècnic La Fe, Valencia, ES, ³Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, Badalona, ES, ⁴Hospital Clínico Universitario Virgen de la Victoria, Málaga, ES, ⁵Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, ⁶Aix Marseille University, APHM, Marseille, FR, ⁷Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ⁸University Hospital of Nantes, Nantes, FR, ⁹Humanitas University, Department of Biomedical Sciences, Rozzano-Milano, IT, ¹⁰Università Politecnica Marche, AOU Ospedali Riuniti, Ancona, IT, ¹¹Institut Gustave Roussy, Villejuif, FR, ¹²A Bristol Myers Squibb Company, Seville, ES, ¹³Bristol Myers Squibb, Princeton, US, ¹⁴Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES
- 12:00 - 12:00 **51P - Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): association with prognosis and tumor immune microenvironment (TIME) features**
- L. Bonanno¹, A. Dal Maso², A. Pavan³, E. Zulato¹, G. Esposito⁴, M. Fassan², G. Nardo¹, G. Pasello⁵, V. Guarneri⁶, F. Calabrese², F. Rea², S. Indraccolo⁷, P.F. Conte⁸, ¹Istituto Oncologico Veneto IOV - IRCCS, Padova, IT, ²Università degli Studi di Padova, Padova, IT, ³AULSS 3 Serenissima, Mestre, IT, ⁴Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, IT, ⁵University of Padova, Padova, IT, ⁶Istituto Oncologico Veneto IRCCS, Padova, IT, ⁷Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁸University of Padova and Oncologia Medica, Padova, IT
- 12:00 - 12:00 **52P - Genetic and clinical profiling of a cohort of extended small cell lung carcinoma**
- E. Vida Navas, J. Chamorro Pérez, E. Corral De La Fuente, Y. Lage, A. Gómez Rueda, J. Torres Jimenez, L. Sanz Gómez, J.J. Soto Castillo, P. Alvarez Ballesteros, J. Esteban Villarrubia, V. Albarrán Fernández, D.I. Rosero Rodríguez, M. San Román Gil, J. Pozas Pérez, M. Lario, A. Caminoa Lizarralde, P. Garrido Lopez, M.E. Olmedo García, Hospital Universitario Ramon y Cajal, Madrid, ES
- 12:00 - 12:00 **53P - Antitumoral effects of the Met inhibitor savolitinib in combination with durvalumab in a syngeneic small cell lung cancer mouse model**
- R. Del Rey-Vergara¹, M.A. Galindo-Campos¹, M. Hardy-Werbin¹, L. Moliner², A. Ríos-Hoyo², C. Martínez³, M. Carpes³, S. González-Gallardo¹, Á. Taus², A. Rovira¹, E. Arriola², ¹IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, ES, ²Hospital del Mar, Barcelona, ES, ³IMIB-LAIB-Arrixaca, Murcia, ES
- 12:00 - 12:00 **54P - Determining the utilization and clinical impact of platinum-etoposide for treatment of small-cell lung cancer in the routine setting**

K. Dimitriou¹, F. Bozorgmehr¹, S. Liersch¹, R. Elshafie², J. Kuon¹, L.-A. Dinges³, T. Eichkorn³, C.-P. Heussel⁴, F. Eichhorn¹, H. Winter⁴, M. Schneider⁴, F. Herth⁴, M. Steins¹, A. Stenzinger⁵, M. Thomas⁶, P. Christopoulos⁷, ¹Thoraxklinik Heidelberg, Heidelberg, DE, ²Heidelberg University Hospital and Translational Research Center Heidelberg, Heidelberg, DE, ³Heidelberg University Hospital, Heidelberg, DE, ⁴Thoraxklinik Heidelberg and Translational Research Center Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, DE, ⁵Institute of Pathology, University Hospital Heidelberg, Heidelberg, DE, ⁶University of Heidelberg, Heidelberg, DE, ⁷Thoraxklinik Heidelberg and Translational Research Center Heidelberg, Heidelberg, DE

12:00 - 12:00

55P - Assessment of cardiovascular biomarkers for individualised treatment decision in small cell lung cancer (SCLC)

E. Gezelius¹, P.-O. Bendahl¹, W. Gallo², K. Goncalves De Oliveira¹, L. Ek³, B. Bergman⁴, J. Sundberg³, O. Melander², M. Belting¹, ¹Lund University - Faculty of Medicine, Lund, SE, ²Lund University - Faculty of Medicine, Malmo, SE, ³Skåne University Hospital, Lund, SE, ⁴Sahlgrenska University Hospital, Gothenburg, SE

12:00 - 12:00

56P - Long-time secondhand smoking as an independent prognostic factor in female patients with small cell lung cancer: a Chinese cohort study using propensity score matching

L. Yuqiong¹, H. Qiang¹, X. Fan², T. Chu², ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, shanghai, CN

12:00 - 12:00

57P - Prognostic role of lung immune scores for prediction of survival in limited-stage small cell lung cancer

L. Käsmann, L. Schnöller, J. Taugner, C. Eze, C. Belka, F. Manapov, Ludwig Maximilians University - Grosshadern, Munich, DE

12:00 - 12:00

58P - Outcome and toxicity of reirradiation for locally recurrent small cell lung cancer; an international multicenter study

L. Käsmann¹, S. Janssen², A. Baschnagel³, T. Kruser⁴, H. Harada⁵, M. Aktan⁶, D. Rades², ¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²University of Luebeck, Luebeck, DE, ³University of Wisconsin, Madison, US, ⁴Northwestern University, Chicago, US, ⁵Shizuoka Cancer Center, Shizuoka, JP, ⁶Necmettin Erbakan University, Konya, TR

12:00 - 12:00

59P - Patterns of recurrence and survival after complete resection of pathological stage N2 small-cell lung cancer

L. Yu, J. Xu, R. Qiao, H. Zhong, B. Han, R. Zhong, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00

60TiP - ORIENTAL: An Open Label, Multicenter, Phase IIIb Study of First-Line Durvalumab plus Platinum-Based Chemotherapy in Chinese Patients with Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Y. Cheng¹, J. Wang², S. Cang³, L. Cao⁴, E. Chen⁵, X. Dong⁶, Y. Fan⁷, B. Gao⁸, Q. Guo⁹, D. Huang¹⁰, S. Li¹¹, A. Liu¹², D. Lv¹³, Y. Pan¹⁴, K. Tang¹⁵, W. Yao¹⁶, F. Ye¹⁷, Y. Yu¹⁸, A. Zang¹⁹, M. Gao²⁰, ¹Jilin Provincial Cancer Hospital, Changchun, CN, ²National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical

College, Beijing, CN, ³Henan Provincial People's Hospital, Zhengzhou, CN, ⁴The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, CN, ⁵Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁶Wuhan Union Hospital, Wuhan, CN, ⁷Zhejiang Cancer Hospital, Hangzhou, CN, ⁸Ruijin Hospital, Shanghai, CN, ⁹Shandong Cancer Hospital and Institute, Jinan, CN, ¹⁰Tianjin Lung Cancer Center, Tianjin, CN, ¹¹Huashan Hospital, Fudan University, Shanghai, CN, ¹²the Second Affiliated Hospital of Nanchang University, Nanchang, CN, ¹³Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, CN, ¹⁴The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, CN, ¹⁵The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ¹⁶Sichuan Provincial Cancer Hospital, Chengdu, CN, ¹⁷First affiliated Hospital of Xiamen University, Xiamen, CN, ¹⁸Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁹Affiliated Hospital of Hebei University, Baoding, CN, ²⁰AstraZeneca China, Shanghai, CN

12:00 - 12:00 **Early stage NSCLC**

12:00 - 12:00 **65P - EGFR mutation (EGFRm) prevalence and mortality in patients with stage IB-IIIa NSCLC: a cohort study in Denmark**

E. Jakobsen¹, A. Taylor², V. Ehrenstein³, ¹Odense University Hospital, Odense, DK, ²AstraZeneca, Cambridge, GB, ³Aarhus University, Aarhus, DK

12:00 - 12:00 **66P - EGFR testing patterns and survival in stage I-III non-small cell lung cancer (NSCLC): analysis using the CancerLinQ Discovery[®] (CLQD) database**

D. Potter¹, P. Sun², J. Li³, L. Luo³, A. Taylor², ¹CancerLinQ, American Society of Clinical Oncology, Alexandria, US, ²AstraZeneca, Cambridge, GB, ³AstraZeneca, Gaithersburg, US

12:00 - 12:00 **67P - Clinical Outcomes of Resected EGFR positive Stage I-III NSCLC patients in the Midlands, UK**

R. Powell¹, N. Murukesh², P. Seeva², A. Solanki³, A. Singh³, A. Jain⁴, A. Elmasry⁵, A. Jegannathan⁵, A. Irwin⁶, Q. Ghafoor⁶, B. O'Sullivan⁶, P. Taniere⁷, S. Baijal⁸, ¹Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, ²Worcestershire Royal Hospital, Worcester, GB, ³Deanesly Centre - New Cross Hospital - The Royal Wolverhampton NHS Trust, Wolverhampton, GB, ⁴The Royal Wolverhampton Hospitals NHS Trust New Cross Hospital, Wolverhampton, GB, ⁵University Hospitals of North Midlands, Stoke on Trent, GB, ⁶New Queen Elizabeth Hospital Birmingham, Birmingham, GB, ⁷Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, ⁸Heartlands Hospital-Heart of England NHS Foundation Trust, Birmingham, GB

12:00 - 12:00 **68P - Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations**

W. Liang¹, Q. He¹, C. Li¹, H. Liang¹, B. Cheng¹, J. He², ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²Guangzhou Medical University, Guangzhou, CN

- 12:00 - 12:00 **69P - VMAT based SBRT in early stage NSCLC: outcomes and toxicities**
E. Martin Garcia, Hospital Universitari i Politècnic La Fe, Valencia, ES
- 12:00 - 12:00 **70P - 4D CT analysis of organs at risk (OARs) in stereotactic radiotherapy**
V. Nardone¹, F.M. Giugliano¹, A. Reginelli², S. Cappabianca³, M. Mormile¹, C. Guida¹,
1UOC Radioterapia, Ospedale del Mare, Napoli, IT, 2Department of Precision Medicine,
University of Campania, Naples, IT, 3Università degli Studi della Campania Luigi
Vanvitelli, caserta, IT
- 12:00 - 12:00 **71P - Assessment of Chest Wall Toxicity after SABR for Early Stage Lung Cancers and Osteoporotic risk.**
D. Abhi¹, J. Wood², K. Mactier², I. Phillips¹, T. Evans², 1Edinburgh Cancer Centre,
Edinburgh, GB, 2Edinburgh Cancer Centre - SCAN, Edinburgh, GB
- 12:00 - 12:00 **72P - Reduction or Elimination of Opioids Following Robotic Lobectomy**
A. De Hoyos¹, E. Stone², E. Jaruseski², S. Brinkman², C. Lawson², 1Ascension Columbia-
St Mary, Milwaukee, US, 2Ascension Columbia St Mary, Milwaukee, US
- 12:00 - 12:00 **73P - Comparison effectiveness of different treatment tactics in patients with non-small cell lung cancer (stage 1A-2B) and positive resection margin: systematic review**
A. Ryzhov, Center for Healthcare of the Ministry of Health of the Russian Federation,
Moscow, RU
- 12:00 - 12:00 **74P - EBUS-TBNA/EUS-B for detecting N2/N3 disease in radiologically N0/N1 Non-Small-Cell Lung Cancer**
S. Sousa¹, M. Valério¹, J. Caldeira¹, M. Santis², P. Matos², A.L. Fonseca², L. Barradas²,
1CHUC - Centro Hospitalar e Universitário de Coimbra, Coimbra, PT, 2Instituto
Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT
- 12:00 - 12:00 **75P - Locally Advanced, Stage III Non-Small Cell Lung Cancer - A Highly Heterogenous Patient Population**
M. Soares¹, S. Gonçalves-Monteiro², L. Antunes³, F. Bernardo⁴, S. Figueiredo⁴, M.
Borges², M.J. Bento⁵, P. Redondo², 1Instituto Portugues de Oncologia Centro do
Porto(IPO-Porto), Porto, PT, 2Management, Outcomes Research and Economics in
Healthcare Group, IPO Porto Research Center (CI-IPO), Portuguese Oncology Institute of
Porto (IPO Porto), Porto, Portugal, Porto, PT, 3Cancer Epidemiology Group, IPO Porto
Research Center (CI-IPO), Portuguese Oncology Institute of Porto (IPO Porto), Porto,
Portugal, Porto, PT, 4AstraZeneca Portugal, Barcarena, PT, 5Cancer Epidemiology
Group, IPO Porto Research Center (CI-IPO), Portuguese Oncology Institute of Porto (IPO
Porto) .Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, PT
- 12:00 - 12:00 **76P - Epithelial-to-Mesenchymal Transition Circulating Tumor Cells subtype as a biomarker in resectable NSCLC**
M.J. Moyano Rodriguez¹, C.I. Bayarri-Lara¹, D. De Miguel-Perez², P. Bravo-Carmona¹, A.
Garcia-Diaz², M.J. Serrano-Fernandez², 1Hospital Universitario Virgen de las Nieves,

Granada, ES, ²Centro de Genómica e Investigación Oncológica (GENYO), Granada, ES

- 12:00 - 12:00 **77TiP - From Liquid Biopsy to Cure: Using CtDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy after Non-Small Cell Lung Cancer (NSCLC) Resection**
D. Kelly¹, L. Le¹, J. Law¹, T. Stockley², T. Waddell³, S. Bratman¹, N. Leigh¹, ¹University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²University Health Network, Toronto, CA, ³Toronto General Hospital, Toronto, CA
- 12:00 - 12:00 **Locally advanced NSCLC**
- 12:00 - 12:00 **80P - Prospective analysis of patients with non-small cell lung cancer (NSCLC) receiving neoadjuvant (chemo-)immunotherapy (C-IO) prior to resection or definitive radiochemotherapy (RCT) in routine clinical care (KOMPASS neo)**
M. Faehling¹, A. Türk¹, R. Saetzler¹, S. Fallscheer¹, J. Sträter², S. Eschmann³, F. Heinzelmann¹, H. Witte⁴, ¹Klinikum Esslingen, Esslingen am Neckar, DE, ²Institut für Pathologie, Esslingen, DE, ³Marienhospital Stuttgart, Stuttgart, DE, ⁴Bundeswehrkrankenhaus, Ulm, DE
- 12:00 - 12:00 **81P - Predictive molecular parameters of pneumonitis development in stage IIIA NSCLC patients treated with neo-adjuvant chemo-immunotherapy from Nadim clinical trial**
B. Sierra-Rodero¹, Y. Garitaonandia², M. Martinez-Cutillas², E. Nadal³, A. Insa⁴, M.R. Garcia Campelo⁵, J. Casal Rubio⁶, M. Domine Gomez⁷, M. Majem Tarruella⁸, D. Rodriguez Abreu⁹, A. Martinez-Marti¹⁰, J. De Castro Carpeno¹¹, E. Del Barco¹², N. Viñolas¹³, I.C. Barneto Aranda¹⁴, B. Massuti Sureda¹⁵, M. Casarrubios¹, R. Laza-Briviesca¹, A. Cruz-Bermudez¹, M. Provencio², ¹Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, ES, ²Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, ³ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ⁴Hospital Clínico Universitario de Valencia, Valencia, ES, ⁵Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁶Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁷University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁸Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, ¹⁰Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ¹¹Hospital Universitario La Paz, Madrid, ES, ¹²University Hospital of Salamanca, Salamanca, ES, ¹³Hospital Clinic of Barcelona, Barcelona, ES, ¹⁴University Hospital Reina Sofia, Cordoba, ES, ¹⁵Hospital General Universitario de Alicante, Alicante, ES
- 12:00 - 12:00 **82P - Multicenter analysis of neoadjuvant (chemo-)immunotherapy (C-IO) in stage IIB-IVB non-small cell lung cancer (NSCLC) resulting in curative surgery in routine clinical care (KOMPASS neo OP)**
M. Faehling¹, C. Meyer Zum Büschenfelde², M. Sebastian³, H. Witte⁴, M. Ulmer⁵, A. Türk¹, R. Saetzler¹, K. Steinestel⁶, W. Brueckl⁷, A. Bleckmann⁸, ¹Klinikum Esslingen, Esslingen am Neckar, DE, ²St.Vincentius-Kliniken Karlsruhe, Karlsruhe, DE,

³Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ⁴Bundeswehrkrankenhaus, Ulm, DE, ⁵Klinikum Ludwigsburg Medizinische Klinik I, Ludwigsburg, DE, ⁶University Hospital of Münster, Münster, DE, ⁷Klinikum Nuernberg Nord, Nürnberg, DE, ⁸UKM - University Hospital of Muenster, Muenster, DE

- 12:00 - 12:00 **83P - Evaluation of the prognostic significance of PD-L1 expression after combined radiochemotherapy in patients with stage III NSCLC**
J. Wagner¹, J. Roeper¹, K. Willborn², L. Heukamp³, F. Griesinger⁴, ¹University of Oldenburg, Oldenburg, DE, ²Pius Hospital, Oldenburg, DE, ³Hematopathology Hamburg, Hamburg, DE, ⁴Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE
- 12:00 - 12:00 **84P - Impact of PTV on Progression-Free Survival in inoperable stage III Non-Small Cell Lung Cancer Patients treated with Chemoradioimmunotherapy**
J. Taugner¹, M. Karin¹, L. Kaesmann¹, C. Eze¹, B. Flörsch¹, J. Guggenberger¹, A. Tufman², C. Belka¹, F. Manapov¹, ¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²LMU Klinikum der Universität München, Munich, DE
- 12:00 - 12:00 **85P - Real-world analysis of treatment patterns and efficacy of durvalumab maintenance after chemoradiotherapy in NSCLC patients**
J. Taugner¹, L. Käsmann¹, C. Eze¹, A. Rühle², A. Tufman³, N. Reinmuth⁴, T. Duell⁴, C. Belka¹, F. Manapov¹, ¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²Uniklinikum Freiburg, Freiburg, DE, ³LMU Klinikum der Universität München, Munich, DE, ⁴Asklepios-Fachklinikum, Gauting, DE
- 12:00 - 12:00 **86P - Post-operative Radiotherapy (PORT) vs Non-PORT in Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis**
A. Hadisurya¹, F. Tandy¹, M. Suciningtias¹, R. Heriyanto², C. Chrystelle¹, F. Wijovi², A. Tancherla², T. Hariyanto¹, A. Kurniawan³, ¹UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ²Faculty of Medicine Pelita Harapan University, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID
- 12:00 - 12:00 **87P - Impact of chemoradiotherapy on the survival of patients with stage III NSCLC**
R. Basto, J. Correia Magalhães, M.J. De Sousa, J. Monteiro, I. Domingues, E. Jesus, G. Sousa, Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT
- 12:00 - 12:00 **88P - Curative treatment in EGFR mt+ NSCLC stage III by induction TKI-chemotherapy combination: feasibility and outcome in 10 cases**
F. Griesinger¹, J. Roeper², K. Willborn³, R. Prenzel³, D. Scriba³, M. Sebastian⁴, ¹Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE, ²University of Oldenburg, Oldenburg, DE, ³Pius Hospital, Oldenburg, DE, ⁴Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE
- 12:00 - 12:00 **89P - Long-Term Clinical Outcomes and Prognostic Factors of Upfront Surgery as a First-Line Therapy in Pathological N2 NSCLC**
L. Bertolaccini, E. Prisciandaro, G. Sedda, L. Girelli, L. Spaggiari, IEO, European Institute

of Oncology IRCCS, Milan, IT

- 12:00 - 12:00 **90P - Salvage radiotherapy for locoregional recurrence after lung cancer resection - a UK cohort**
R. Li, H. Ariyaratne, Royal Free London NHS Foundation Trust, London, GB
- 12:00 - 12:00 **91P - The role of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) in the diagnosis of Large Cell Neuroendocrine Carcinoma (LCNEC)**
B. Teng, M. Rice, D. Rana, D. Shelton, N. Narine, H. Al-Najjar, Manchester University Foundation Trust, Manchester, GB
- 12:00 - 12:00 **92P - Neuroimaging in staging patients for curative intent stage II and III non-small cell lung cancer**
S. Growcott, J. Page, S. Foster, J. Walther, Musgrove Park Hospital - Taunton and Somerset NHS Foundation Trust, Taunton, GB
- 12:00 - 12:00 **93TiP - MERMAID-2: Phase 3 study of durvalumab in patients with resected, Stage II-III NSCLC who become MRD+ after curative-intent therapy**
D. Spigel¹, S. Peters², M.-J. Ahn³, M. Tsuboi⁴, J. Chaft⁵, D. Harpole⁶, F. Barlesi⁷, C. Abbosh⁸, H. Mann⁹, R. May¹⁰, P. Dennis¹⁰, C. Swanton¹¹, ¹Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ²Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ³Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Division of Thoracic Surgery and Oncology National Cancer Center Hospital East, Kashiwa, JP, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Duke University Medical Center, Durham, US, ⁷Gustave Roussy Cancer Campus, Villejuif, FR, ⁸Cancer Research UK Lung Cancer Centre, University College London Cancer Institute, London, GB, ⁹AstraZeneca, Cambridge, GB, ¹⁰AstraZeneca, Gaithersburg, US, ¹¹The Francis Crick Institute/Cancer Research UK Lung Cancer Centre, University College London Cancer Institute/University College London Hospitals Foundation Trust, London, GB
- 12:00 - 12:00 **94TiP - Neoadjuvant Tislelizumab or Placebo + Platinum-Based Chemotherapy Followed by Adjuvant Tislelizumab or Placebo in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC): A Phase 3 Trial in Progress**
C. Wang¹, R. Wang², Y. Ma², X. Liang², ¹Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ²BeiGene (Shanghai) Co., Ltd., Shanghai, CN
- 12:00 - 12:00 **95TiP - DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, Stage III NSCLC ineligible for chemotherapy**
A. Filippi¹, R. Dziadziuszko², M.R. Garcia Campelo³, J.-B. Paoli⁴, W. Sawyer⁵, I.E. Díaz Pérez⁶, ¹Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia PV, IT, ²Medical University of Gdansk, Gdansk, PL, ³Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁴Hôpital Saint Joseph, Marseille, FR, ⁵AstraZeneca, Cambridge, GB, ⁶AstraZeneca, Gaithersburg, US
- 12:00 - 12:00 **Advanced NSCLC**

- 12:00 - 12:00 **102P - Primary results from the China Cohort of IMpower132: atezolizumab (atezo) + carboplatin (carbo) or cisplatin (cis) + pemetrexed (pem) as first-line therapy in advanced NSCLC**
- S. Lu¹, J. Fang², Z. Wang², Y. Fan³, Y. Liu⁴, J. He⁵, B. Cao⁶, J. Zhou⁷, J. Hu⁸, J. Xia⁹, W. Liu⁹, J. Shi⁹, J. Yi¹⁰, L. Cao¹¹, ¹Shanghai Chest Hospital, Shanghai, CN, ²Beijing Cancer Hospital, Beijing, CN, ³Zhejiang Cancer Hospital, Hangzhou, CN, ⁴First Hospital, China Medical University, Shenyang, CN, ⁵Guangzhou Medical University, Guangzhou, CN, ⁶Beijing Friendship Hospital, Capital Medical University, Beijing, CN, ⁷Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ⁸Zhongshan, Fudan University, Shanghai, CN, ⁹F. Hoffmann-La Roche Ltd, Shanghai, CN, ¹⁰Genentech, Inc, South San Francisco, US, ¹¹The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, CN
- 12:00 - 12:00 **103P - First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)**
- Z. Andric¹, G. Gálffy², M. Cobo Dols³, B. Szima⁴, G. Stojanovic⁵, M. Petrovic⁶, E. Felip⁷, D. Vicente Baz⁸, S. Ponce Aix⁹, O. Juan-Vidal¹⁰, S. Tehenes¹¹, Z. Szalai¹², G. Losonczy¹³, A. Calles Blanco¹⁴, R. Bernabe¹⁵, K. Duecker¹⁶, D. Zhou¹⁶, A. Schroeder¹⁶, G. Guezel¹⁶, F. Ciardiello¹⁷, ¹Clinical Hospital Center Bezanijska Kosa, Belgrade, RS, ²Pulmonology Hospital Törökbálint, Törökbálint, HU, ³Hospital Regional Universitario de Málaga, IBIMA, Malaga, ES, ⁴Markusovszky Hospital, Szombathely, HU, ⁵Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica, RS, ⁶Clinic for Pulmonology, Clinical Center Kragujevac, Kragujevac, RS, ⁷Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁸Hospital Universitario Virgen Macarena, Sevilla, ES, ⁹Hospital Universitario 12 de Octubre, Universidad Complutense and Ciberonc, Madrid, ES, ¹⁰Hospital Universitari I Politècnic La Fe, Valencia, ES, ¹¹St. Raphael Hospital of Zala County, Zalaegerszeg, HU, ¹²Aladar Petz University Teaching Hospital, Győr, HU, ¹³Semmelweis University I. Faculty of Medicine, Budapest, HU, ¹⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁵Hospital Universitario Virgen del Rocío, Seville, ES, ¹⁶Merck KGaA, Darmstadt, DE, ¹⁷Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 12:00 - 12:00 **104P - Fast progression in high PD-L1 NSCLC treated with Pembrolizumab in first-line: a prognostic scoring system based on clinical features**
- A. Passaro¹, D. Giannarelli², E. Bria³, S. Novello⁴, D. Galetta⁵, A. Gelibter⁶, M.L. Reale⁴, S. Carnio⁷, E. Vita³, A. Stefani³, P. Pizzutilo⁵, V. Stati¹, I. Attili¹, F. De Marinis¹, ¹European Institute of Oncology, IRCCS, Milan, IT, ²Istituto Nazionale Tumori Regina Elena, IRCCS, Rome, IT, ³Comprehensive Cancer Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, IT, ⁴San Luigi Gonzaga Hospital, University of Turin, Orbassano, IT, ⁵IRCCS Oncologico Giovanni Paolo II, Bari, IT, ⁶Policlinico Umberto I - Sapienza University of Rome, Rome, IT, ⁷Università Degli Studi Di Torino - Orbassano, Orbassano, IT
- 12:00 - 12:00 **105P - Real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy in PD-L1 TPS ≥50% advanced NSCLC: 3-year follow-up data**
- V. Velcheti¹, X. Hu², Y. Li², T. Burke², B. Piperdi², ¹New York University School of Medicine, New York, US, ²Merck & Co., Inc., Kenilworth, US
- 12:00 - 12:00 **106P - Predicting response to Pembrolizumab in metastatic Non-Small Cell Lung**

Cancer (NSCLC): clinical usefulness of peripheral Lymphocyte-Monocyte Ratio and baseline FDG-Uptake

L. Raimondi¹, M. Montebello², F. Corica², P. Ciraci², G.P. Spinelli³, ¹Sapienza University of Rome, Rome, IT, ²Policlinico Umberto I - Università La Sapienza, Roma, Rome, IT, ³Oncologia Universitaria ASL Aprilia, Aprilia, IT

12:00 - 12:00 **107P - Baseline total metabolic tumor volume on [18F]FDG PET/CT as promising biomarker in advanced NSCLC patients treated with first line pembrolizumab.**

F. Dall'Olio¹, D. Calabrò², N. Conci³, G. Argalia², P. Marchese⁴, F. Fabbri⁴, B. Fragomeno⁴, S. Fanti², V. Ambrosini², A. Ardizzoni³, ¹AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ²Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy;, Bologna, IT, ³University of Bologna, Bologna, IT, ⁴Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna -Italia, Bologna, IT

12:00 - 12:00 **108P - Real-World Time on Treatment (rwToT) Analysis for First-Line Pembrolizumab Combination Therapy in Advanced Nonsquamous NSCLC**

S. Liu¹, X. Hu², Y. Li², T. Burke², B. Piperdi², ¹Lombardi Cancer Center Georgetown University, Washington, US, ²Merck & Co., Inc., Kenilworth, US

12:00 - 12:00 **109P - Real-world evaluation of Pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France**

M. Perol¹, T. Filleron², X. Quantin³, C. Chouaid⁴, C. Audigier Valette⁵, H. Lena⁶, C. Kaderbhai⁷, C. Fabre⁸, M. Santorelli⁹, L. Bensimon¹⁰, T. Burke¹¹, D. Couch¹², E. Nguyen¹², C. Courtinard¹², E. Lung Cancer Group¹², ¹Léon Bérard Cancer Center, Lyon, FR, ²Centre Claudius-Regaud, Toulouse, FR, ³ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁴CH Intercommunal de Créteil, Créteil, FR, ⁵Hopital Sainte Musse, Toulon, FR, ⁶CHU de Pontchaillou, Rennes, FR, ⁷Centre Georges Francois Leclerc, Dijon, FR, ⁸Capionis, IQVIA Company (France), Courbevoie, FR, ⁹Merck & Co, Rahway, US, ¹⁰MSD France, Puteaux, FR, ¹¹Merck & Co., Inc., Kenilworth, US, ¹²Unicancer, Paris, FR

12:00 - 12:00 **110P - Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France**

M. Perol¹, X. Quantin², H. Lena³, T. Filleron⁴, C. Chouaid⁵, C. Audigier Valette⁶, C. Kaderbhai⁷, G. Chenuc⁸, M. Santorelli⁹, L. Bensimon¹⁰, T. Burke¹¹, G. Simon¹², A.-L. Martin¹², D. Debievre¹³, R. Gervais¹⁴, R. Schott¹⁵, M. Carton¹⁶, C. Courtinard¹², N. Girard¹⁶, E. Lung Cancer Group¹², ¹Léon Bérard Cancer Center, Lyon, FR, ²ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ³CHU de Pontchaillou, Rennes, FR, ⁴Centre Claudius-Regaud, Toulouse, FR, ⁵CH Intercommunal de Créteil, Créteil, FR, ⁶Hopital Sainte Musse, Toulon, FR, ⁷Centre Georges Francois Leclerc, Dijon, FR, ⁸Capionis, IQVIA Company (France), Courbevoie, FR, ⁹Merck & Co, Rahway, US, ¹⁰MSD France, Puteaux, FR, ¹¹Merck & Co., Inc., Kenilworth, US, ¹²Unicancer, Paris, FR, ¹³GH Mulhouse, Mulhouse, FR, ¹⁴Centre Francois Baclesse, Caen, FR, ¹⁵ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹⁶Institut Curie, Paris, FR

12:00 - 12:00 **111P - Advanced non-small cell lung cancer with PD-L1$\geq 50\%$: Pembrolizumab alone or combined with chemotherapy**

B. Han, B. Han, B. Zhang, M. Hu, Y. Wang, Z. Yang, W. Zhang, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

- 12:00 - 12:00 **112P - Atezolizumab As First-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis on Overall Survival**
E. Marcella¹, B. Susanto¹, S. Chen², J. Tandiono², A. Tancherla¹, R. Heriyanto¹, F. Wijovi¹, A. Kurniawan³, ¹Faculty of Medicine Pelita Harapan University, Tangerang, ID, ²UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID
- 12:00 - 12:00 **113P - Comparative efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or in addition to chemotherapy for advanced, PD-L1 high non-small cell lung cancer (NSCLC): a meta-analysis of randomized trials**
A. Di Federico¹, A. De Giglio¹, G. Nuvola¹, C. Deiana¹, N. Conci¹, C. Bonucci¹, G. Donati¹, C. Parisi¹, F. Gelsomino², A. Ardizzoni¹, ¹University of Bologna, Bologna, IT, ²Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT
- 12:00 - 12:00 **114P - Nivolumab plus Ipilimumab As First-line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review**
J. Tandiono¹, S. Chen¹, E. Marcella², B. Susanto², R. Heriyanto², F. Wijovi², A. Tancherla², A. Kurniawan³, ¹UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ²Faculty of Medicine Pelita Harapan University, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID
- 12:00 - 12:00 **115P - Survival data from EMPOWER-Lung 4: Phase 2 study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small-cell lung cancer (NSCLC)**
B.Y. Shim¹, S. Lee², J. De Castro Carpeño³, C.-H. Chiu⁴, M. Cobo Dols⁵, H.R. Kim⁶, J.S. Ryu⁷, M. Majem Tarruella⁸, Y. Summers⁹, C. Thomas¹⁰, Y. Xu², I. Lowy², P. Rietschel², ¹St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, KR, ²Regeneron Pharmaceuticals, Inc., Tarrytown, US, ³Hospital Universitario La Paz, Madrid, ES, ⁴Taipei Veterans General Hospital/School of Medicine, National Yang-Ming University, Taipei, TW, ⁵Hospital Regional Universitario de Málaga, IBIMA, Malaga, ES, ⁶Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁷Inha University Hospital, Incheon, KR, ⁸Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹The Christie NHS Foundation Trust/Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, GB, ¹⁰New England Cancer Specialists, Scarborough, US
- 12:00 - 12:00 **116P - Real world outcomes of patients with metastatic non-small cell lung cancer receiving 2L+ atezolizumab-based treatments in Taiwan clinical practice**
S.-G. Wu¹, C.-L. Chiang², C.-C. Wang³, J.-Y. Hung⁴, T.-C. Hsia⁵, C.-Y. Su⁶, C.-F. Chen⁶, C.-H. Kuo⁷, J.-Y. Shih⁸, ¹National Taiwan University Hospital, Taipei City, TW, ²Taipei Veterans General Hospital, Taipei, TW, ³Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, TW, ⁴Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW, ⁵Department of Internal Medicine, China Medical University Hospital, Department of Respiratory Therapy, China Medical University,

Taichung, TW, ⁶Medical Division, Roche Products Ltd, Taipei, TW, ⁷Chang Gung Memorial Hospital, Taipei, TW, ⁸Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, TW

12:00 - 12:00

117P - Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients

A. Cortellini¹, S. Buti², M. Di Maio³, R. Giusti⁴, O. Nigro⁵, L. Cantini⁶, E. Bria⁷, F. Grossi⁸, M. Torniai⁹, M. De Tursi¹⁰, F. Citarella¹¹, F. Mazzoni¹², A. Gelibter¹³, M. Macerelli¹⁴, M.R. Migliorino¹⁵, A. Russo¹⁶, A. Addeo¹⁷, G. Porzio¹, C. Ficorella¹⁸, D. Pinato¹⁹, ¹Ospedale Civile San Salvatore, L'Aquila, IT, ²University Hospital of Parma, Parma, IT, ³University of Turin, Ordine Mauriziano Hospital, Torino, IT, ⁴St. Andrea Hospital of Rome, Rome, IT, ⁵ASST-Sette Laghi, Varese, Varese, IT, ⁶AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, ⁷Comprehensive Cancer Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, IT, ⁸Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT, ⁹AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT, ¹⁰Università G. D'Annunzio, Chieti-Pescara, Chieti, IT, ¹¹Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹²Azienda Ospedaliera Universitaria Careggi, Firenze, IT, ¹³Policlinico Umberto I - Sapienza University of Rome, Rome, IT, ¹⁴Azienda Sanitaria Universitaria Integrata of Udine - Santa Maria della Misericordia Hospital, Udine, IT, ¹⁵Azienda Ospedaliera S. Camillo Forlanini, Rome, IT, ¹⁶University of Messina, Messina, IT, ¹⁷HUG, Geneva, CH, ¹⁸Università degli Studi dell'Aquila, L'Aquila, IT, ¹⁹Imperial College London - Hammersmith Hospital, London, GB

12:00 - 12:00

118P - The clinical utility of advanced lung inflammation index (ALI) for immunotherapy guidance in non-small-cell lung cancer

G. Mountzios¹, E. Samantas², K. Senghas³, J. Krisam⁴, S. Angelaki⁵, G. Pentheroudakis⁶, A. Psyrris⁷, P. Kosmidis⁸, R. Elshafie⁹, H. Linardou¹⁰, F. Herth¹¹, M. Meister³, T. Muley³, E. Razis¹², A. Stenzinger¹³, I. Boukovinas¹⁴, M. Reck¹⁵, K. Syrigos¹⁶, M. Thomas¹⁷, P. Christopoulos¹⁸, ¹Henry Dunant Hospital Centre, Athens, GR, ²Metropolitan Hospital, Faliro, GR, ³Thoraxklinik at Heidelberg University Hospital, Heidelberg/Germany,, Heidelberg, DE, ⁴Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, DE, ⁵University Hospital of Heraklion (PAGNI), Heraklion, GR, ⁶ESMO - European Society for Medical Oncology, Lugano, CH, ⁷Attikon University Hospital, Haidari, GR, ⁸Hygeia Hospital, Athens, GR, ⁹Heidelberg University Hospital and Translational Research Center Heidelberg, Heidelberg, DE, ¹⁰Metropolitan Hospital, Athens, GR, ¹¹Thoraxklinik Heidelberg and Translational Research Center Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, DE, ¹²Hygeia Hospital, Marousi, GR, ¹³Institute of Pathology, University Hospital Heidelberg, Heidelberg, DE, ¹⁴Bioclinic Oncology Unit of Thessaloniki, Athens, GR, ¹⁵Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ¹⁶University of Athens, Sotiria General Chest Diseases Hospital, Athens, GR, ¹⁷University of Heidelberg, Heidelberg, DE, ¹⁸Thoraxklinik Heidelberg and Translational Research Center Heidelberg, Heidelberg, DE

12:00 - 12:00

119P - The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced Non-small cell lung cancer (aNSCLC) patients (pts)

A. Dal Maso¹, A. Pavan², A. Ferro¹, G. Pretelli¹, S. Frega³, J. Menis⁴, G. Pasello⁴, V.

Guarneri⁵, P.F. Conte⁶, L. Bonanno⁷, ¹Università degli Studi di Padova, Padova, IT, ²AULSS 3 Serenissima, Mestre, IT, ³Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁴University of Padova, Padova, IT, ⁵Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶University of Padova and Oncologia Medica, Padova, IT, ⁷Istituto Oncologico Veneto IOV - IRCCS, Padova, IT

- 12:00 - 12:00 **120P - Checkpoint inhibitors in responding patients with advanced carcinoma Lung , Can we stop treatment? A single center experience.**
R. Ashwath, A. Rauthan, P. Patil, P. Vundemodalu, N. Yashas, G. Nigade, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN
- 12:00 - 12:00 **121P - RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Analysis of RAS and NF1 Co-Mutations in Advanced NSCLC**
H. Adderley¹, M. Aldea², J. Aredo³, M. Carter⁴, M. Church¹, F. Blackhall¹, M. Krebs⁴, H. Wakelee⁵, B. Besse⁶, D. Planchard⁶, D. Vasseur², C. Massard², C. Lindsay⁴, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Institute Gustave Roussy, Villejuif, FR, ³Stanford Cancer Institute, Stanford University, Stanford, US, ⁴Christie Hospital, University of Manchester, Manchester, GB, ⁵Stanford Comprehensive Cancer Institute, Stanford, US, ⁶Institut Gustave Roussy, Villejuif, FR
- 12:00 - 12:00 **122P - STK11 and/or KEAP1 mutations and outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic literature review.**
A. Codima¹, G. Monteiro¹, I. Costa¹, D. Kashiura², L. Torres², G. Julian², G. Harada³, G. Junior¹, ¹University of Sao Paulo - Faculty of Medicine, Sao Paulo, BR, ²IQVIA Real World Insights, Sao Paulo, BR, ³Hospital Sírio-Libanês, Sao Paulo, BR
- 12:00 - 12:00 **123P - Impact of the STK11 mutation on the response to immunotherapy**
A. Kalantari, T. Pieters, K. Sawadogo, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE
- 12:00 - 12:00 **124P - KRAS mutated (mt) Non-small cell lung cancer (NSCLC) and response to antiPD-1/PD-L1 regarding co-mutational status and assessment of KRAS mutation on plasma or tissue biopsy**
E. Corral De La Fuente, J.J. Soto Castillo, A. Gómez Rueda, Y. Lage, M.E. Olmedo García, E. Vida Navas, J. Torres Jimenez, P. Alvarez Ballesteros, M. Lario, A. Benito Berlinches, P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES
- 12:00 - 12:00 **125P - Benefit of immunotherapy in advanced NSCLC patients selected by KRAS mutations: a single institute retrospective analysis.**
J.J. Soto Castillo, E. Corral De La Fuente, M.E. Olmedo García, A. Gómez Rueda, Y. Lage, E. Vida Navas, L. Sanz Gómez, M. Lario, P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES
- 12:00 - 12:00 **126P - Clinical predictive factors in real world setting in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with Immune Checkpoint Inhibitors (ICI).**
A. Callejo¹, D. Marmolejo¹, P. Iranzo¹, J.D. Assaf¹, N. Pardo¹, A. Navarro¹, A. Martinez-Marti¹, S. Cedres¹, N.M. Diaz Mejia², C. Carbonell¹, R. Amat¹, J. Frigola³, E. Felip⁴, ¹Vall

d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

- 12:00 - 12:00 **127P - Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICI).**
P. Iranzo¹, A. Callejo¹, D. Marmolejo¹, J.D. Assaf¹, N. Pardo¹, A. Navarro¹, A. Martinez-Marti¹, S. Cedres¹, N.M. Diaz Mejia², C. Carbonell¹, R. Amat¹, J. Frigola³, E. Felip⁴, ¹Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 12:00 - 12:00 **128P - A real world scenario of applicability of Immuno Oncology agents into practice in NSCLC in a resource constrained setting**
S.C. G., M. Singhal, A. Sharma, S. Valame, D. Panda, Indraprastha Apollo Hospital, New delhi, IN
- 12:00 - 12:00 **129P - Predicting response to immunotherapy in advanced Non-Small-Cell Lung Cancer**
M. Rebordão Pires¹, C.I. De Sousa Amorim Sampaio Da Costa², T. Cunha Pereira², J. Monteiro¹, I. Domingues¹, A.C. Caetano², A.R. Meira Garcia¹, E. Jesus¹, G. Sousa¹, ¹Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ²Portuguese Institute for Oncology of Coimbra, Coimbra, PT
- 12:00 - 12:00 **130P - Neutrophil-to-lymphocyte ratio as a response predictor to immune checkpoint inhibitors in non-small-cell lung cancer**
C.I. De Sousa Amorim Sampaio Da Costa¹, M. Rebordão Pires², J. Monteiro², A.C. Caetano¹, F. Salgueiro², J. Correia Magalhães², M.J. De Sousa², R. Basto², A.R. Meira Garcia², I. Domingues², E. Jesus², G. Sousa², ¹Portuguese Institute for Oncology of Coimbra, Coimbra, PT, ²Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT
- 12:00 - 12:00 **131P - Predictive factors of response to PD-(L)1 inhibitors in patients with advanced non-small cell lung (NSCLC) and high PD-L1 expression**
A. Barba Joaquín¹, A. Piedra¹, J. Mosquera², M. Riudavets Melià³, M.I. Gomez-Randulfe², M.R. Garcia Campelo⁴, I.G. Sullivan¹, J. Serra¹, M. Aguado¹, M. Majem Tarruella⁵, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Hospital Universitario a Coruña, a Coruña, ES, ³Gustave Roussy cancer campus, Villejuif, FR, ⁴Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁵Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, ES
- 12:00 - 12:00 **132P - Stage IV Non-small cell lung cancer stage in the elderly - Real World Data**
J. Monteiro¹, C.I. De Sousa Amorim Sampaio Da Costa², M. Rebordão Pires¹, A.C. Caetano², F. Salgueiro¹, I. Domingues¹, A.R. Meira Garcia¹, E. Jesus¹, N. Bonito³, G. Sousa¹, ¹Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ²Portuguese Institute for Oncology of Coimbra, Coimbra, PT, ³Portuguese Oncology Institute of Coimbra, Coimbra, PT

- 12:00 - 12:00 **133P - Drug - drug interactions (DDIs) in non-small cell lung cancer during chemotherapy - immunotherapy treatment**
M. Occhipinti¹, M. Brambilla¹, G. Galli¹, S. Manglaviti¹, A. Prelaj¹, R. Ferrara¹, A. De Toma¹, T. Beninato¹, E. Zattarin¹, C. Proto¹, G. Lo Russo¹, A. Gelibter², M. Simmaco³, M. Garassino⁴, P. Marchetti², ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ²Policlinico Umberto I - Sapienza University of Rome, Rome, IT, ³Sant'Andrea University Hospital, Rome, IT, ⁴Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 12:00 - 12:00 **134P - Effectiveness of Immune Checkpoint Inhibitor monotherapy for postoperative recurrent Lung Cancer in clinical practice**
T. Sasaki¹, N. Yoshimura², ¹Tohoku Medical and Pharmaceutical University, Sendai, JP, ²Tohoku Medical & Pharmaceutical University Komatsushima Campus, Sendai, JP
- 12:00 - 12:00 **135P - The real-world use of Tyrosine Kinase Inhibitors (TKIs) in Epidermal Growth Factor Receptor mutated (EGFRm) advanced (stage IIIb / IIIc / IV) Non-Small Cell Lung Cancer (NSCLC) patients**
J. Subramanian¹, Y.-L. Choi², T.-Y. Chou³, J. Gregg⁴, R. Hui⁵, N. Leigh⁶, A. Marchetti⁷, N. Navani⁸, T. Bailey⁹, M. Silvey⁹, R. Makin⁹, D. Kahangire¹⁰, M. Chau¹¹, A. Taylor¹⁰, F. Griesinger¹², ¹Saint Luke's Cancer Institute, Kansas City, US, ²Sungkyunkwan University School of Medicine, Seoul, KR, ³Taipei Veterans General Hospital, Taipei, TW, ⁴University of California, Davis, US, ⁵Westmead Hospital and the University of Sydney, Sydney, AU, ⁶University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁷University of Chieti, Chieti, IT, ⁸University College London, London, GB, ⁹Adelphi Real World, Bollington, GB, ¹⁰AstraZeneca, Cambridge, GB, ¹¹AstraZeneca, Gaithersburg, US, ¹²Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE
- 12:00 - 12:00 **136P - Best practice recommendations for molecular analysis of acquired EGFR TKI resistance mechanisms**
L. Hondelink¹, D. Cohen¹, J. Von Der Thüsen², E.J. Dubbink², T. Van Wezel¹, K. Monkhorst³, ¹Leiden University Medical Center, Leiden, NL, ²Erasmus Medical Center, Rotterdam, NL, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:00 - 12:00 **137P - Epidermal Growth Factor Receptor mutation status and response to Tyrosine Kinase Inhibitors in advanced Chinese female lung squamous cell carcinoma: a retrospective study**
Q. Chang, H. Qiang, C. Tianqing, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN
- 12:00 - 12:00 **138P - The impact of variant allele frequency in EGFR mutated NSCLC patients on targeted therapy**
A. Addeo¹, A. Friedlaender², M. Chevallier², C. De Vito², P. Tsantoulis², ¹HUG, Geneva, CH, ²Hopitaux Universitaires de Geneve - HUG, Geneva, CH
- 12:00 - 12:00 **139P - The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy - Real world data**

from two certified lung cancer centers in Germany

J. Roeper¹, P. Christopoulos², M. Falk³, L. Heukamp³, A. Stenzinger⁴, M. Thomas⁵, F. Griesinger⁶, ¹University of Oldenburg, Oldenburg, DE, ²Thoraxklinik Heidelberg and Translational Research Center Heidelberg, Heidelberg, DE, ³Hematopathology Hamburg, Hamburg, DE, ⁴Institute of Pathology, University Hospital Heidelberg, Heidelberg, DE, ⁵University of Heidelberg, Heidelberg, DE, ⁶Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE

12:00 - 12:00 **140P - Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs**

M.L. Reale¹, P. Bironzo¹, L. Righi¹, A. Listi¹, F. Tabbò¹, A. Caglio², C. Pisano¹, V. Napoli¹, M. Di Maio², S. Novello¹, ¹San Luigi Gonzaga Hospital, University of Turin, Orbassano, IT, ²University of Turin, Ordine Mauriziano Hospital, Torino, IT

12:00 - 12:00 **141P - Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib**

M. White¹, J. Neal², R. Gardner³, K. Cunanan³, M. Das², S. Padda², K. Ramchandran², T. Chen⁴, H. Wakelee¹, ¹Stanford Comprehensive Cancer Institute, Stanford, US, ²Stanford Comprehensive Cancer Institute, Palo Alto, US, ³Stanford University School of Medicine, Stanford, US, ⁴Stanford Cancer Center South Bay, San Jose, US

12:00 - 12:00 **142P - EGFR-TKI plus Radiotherapy versus EGFR-TKI Only in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Systematic Review and Meta-Analysis of Observational Studies**

A. Tancherla¹, F. Wijovi¹, T. Hariyanto², A. Kurniawan³, A. Giselvania⁴, ¹Faculty of Medicine Pelita Harapan University, Tangerang, ID, ²UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID, ⁴Dr Cipto Mangunkusumo Hospital-Faculty of Medicine, Universitas Indonesia, Jakarta, ID

12:00 - 12:00 **143P - Physician perceptions of barriers to Epidermal Growth Factor Receptor mutation (EGFRm) testing in advanced (stage IIIb / IIIc / IV) Non-Small Cell Lung Cancer (NSCLC)**

J. Subramanian¹, Y.-L. Choi², T.-Y. Chou³, J. Gregg⁴, R. Hui⁵, N. Leigh⁶, A. Marchetti⁷, N. Navani⁸, T. Bailey⁹, M. Silvey⁹, R. Makin⁹, D. Kahangire¹⁰, M. Chau¹¹, A. Taylor¹⁰, F. Griesinger¹², ¹Saint Luke's Cancer Institute, Kansas City, US, ²Sungkyunkwan University School of Medicine, Seoul, KR, ³Taipei Veterans General Hospital, Taipei, TW, ⁴University of California, Davis, US, ⁵Westmead Hospital and the University of Sydney, Sydney, AU, ⁶University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁷University of Chieti, Chieti, IT, ⁸University College London, London, GB, ⁹Adelphi Real World, Bollington, GB, ¹⁰AstraZeneca, Cambridge, GB, ¹¹AstraZeneca, Gaithersburg, US, ¹²Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE

12:00 - 12:00 **144P - Delays in Epidermal Growth Factor Receptor mutation (EGFRm) testing in advanced (stage IIIb / IIIc / IV) Non-Small Cell Lung Cancer (NSCLC) patients and their impact on the use of first line Tyrosine Kinase Inhibitor (TKIs) in a real-world setting**

F. Griesinger¹, Y.-L. Choi², T.-Y. Chou³, J. Gregg⁴, R. Hui⁵, N. Leigh⁶, A. Marchetti⁷, N. Navani⁸, T. Bailey⁹, M. Silvey⁹, R. Makin⁹, D. Kahangire¹⁰, M. Chau¹¹, A. Taylor¹⁰, J.

Subramanian¹², ¹Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE, ²Sungkyunkwan University School of Medicine, Seoul, KR, ³Taipei Veterans General Hospital, Taipei, TW, ⁴University of California, Davis, US, ⁵Westmead Hospital and the University of Sydney, Sydney, AU, ⁶University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁷University of Chieti, Chieti, IT, ⁸University College London, London, GB, ⁹Adelphi Real World, Bollington, GB, ¹⁰AstraZeneca, Cambridge, GB, ¹¹AstraZeneca, Gaithersburg, US, ¹²Saint Luke's Cancer Institute, Kansas City, US

12:00 - 12:00

145P - UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations

S. Miura¹, T.-C. Hsia², J.-Y. Hung³, H.A. Jung⁴, J.-Y. Shih⁵, T.-Y. Yang⁶, C.-K. Park⁷, S.H. Lee⁸, T. Okamoto⁹, H.K. Ahn¹⁰, Y.C. Lee¹¹, Y. Sato¹², S.S. Lee¹³, C. Mascaux¹⁴, H. Daoud¹⁵, A. Märten¹⁵, S. Popat¹⁶, ¹Division of Respiratory Medicine, Niigata University, Niigata, JP, ²Department of Internal Medicine, China Medical University Hospital, Department of Respiratory Therapy, China Medical University, Taichung, TW, ³Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW, ⁴Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, TW, ⁶Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, TW, ⁷Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, KR, ⁸Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, KR, ⁹Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹⁰Division of Medical Oncology, Gachon University Gil Medical Center, Incheon, KR, ¹¹Chonbuk National University Medical School, Jeonju, KR, ¹²Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, JP, ¹³Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, KR, ¹⁴Pulmonary Department, Strasbourg University, Strasbourg University Hospital, Strasbourg, FR, ¹⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE, ¹⁶The Royal Marsden Hospital - NHS Foundation Trust; Imperial College London; Institute of Cancer Research, London, GB

12:00 - 12:00

146P - The impact of prior immune checkpoint inhibitors or osimertinib treatment on NSCLC patients receiving atezolizumab treatment - a real-world observation

S.-G. Wu¹, C.-L. Chiang², C.-C. Wang³, J.-Y. Hung⁴, T.-C. Hsia⁵, C.-H. Kuo⁶, J.-Y. Shih⁷, ¹National Taiwan University Hospital, Taipei City, TW, ²Taipei Veterans General Hospital, Taipei, TW, ³Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, TW, ⁴Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW, ⁵Department of Internal Medicine, China Medical University Hospital, Department of Respiratory Therapy, China Medical University, Taichung, TW, ⁶Chang Gung Memorial Hospital, Taipei, TW, ⁷Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, TW

- 12:00 - 12:00 **147P - PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients**
Y. Yu¹, L. Xia¹, J. Zhou², K. Wang³, Y. Zhang⁴, C. Zhang⁵, A. Liu⁶, Y. Fan⁴, J. Chang⁷, L. Wang⁸, Y. Liu⁹, S. Lu¹⁰, ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ³The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁴Zhejiang Cancer Hospital, Hangzhou, CN, ⁵Inner Mongolia People's Hospital, Huhhot, CN, ⁶the Second Affiliated Hospital of Nanchang University, Nanchang, CN, ⁷Fudan University Shanghai Cancer Center, Shanghai, CN, ⁸The Comprehensive Cancer Centre of Drum Tower Hospital, Nanjing, CN, ⁹First Hospital, China Medical University, Shenyang, CN, ¹⁰Shanghai Chest Hospital, Shanghai, CN
- 12:00 - 12:00 **148P - Neutrophil to Lymphocyte Ratio as a Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitor: A Systematic Review and Meta-Analysis**
R. Heriyanto¹, J. Tandiono², E. Marcella¹, B. Susanto¹, S. Chen², F. Wijovi¹, A. Tancherla¹, A. Kurniawan³, ¹Faculty of Medicine Pelita Harapan University, Tangerang, ID, ²UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID
- 12:00 - 12:00 **149P - First line (1L) osimertinib in EGFR mutant (mut) advanced non-small-cell lung cancer (aNSCLC) patients (pts): progression (PD) pattern and safety in the real-world (RW)**
M. Lorenzi¹, A. Dal Maso², A. Ferro², V. Polo³, D. Scattolin¹, M. Macerelli⁴, A. Follador⁴, G. Targato⁴, S. Indraccolo⁵, S. Frega⁵, J. Menis⁶, L. Bonanno⁷, V. Guarneri⁸, P.F. Conte⁹, G. Pasello⁶, ¹University of Padua, Padua, IT, ²Università degli Studi di Padova, Padova, IT, ³AULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, IT, ⁴Azienda Sanitaria Universitaria Integrata of Udine - Santa Maria della Misericordia Hospital, Udine, IT, ⁵Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁶University of Padua, Padova, IT, ⁷Istituto Oncologico Veneto IOV - IRCCS, Padova, IT, ⁸Istituto Oncologico Veneto IRCCS, Padova, IT, ⁹University of Padua and Oncologia Medica, Padova, IT
- 12:00 - 12:00 **150P - A phase I study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR+ advanced NSCLC patients failed to prior EGFR TKI therapies**
J. Feng, M. Shi, L. Wang, S. Yu, F. Yan, W. Peng, Jiangsu Cancer Hospital, Nanjing, CN
- 12:00 - 12:00 **151P - Osimertinib versus Standard-of-care EGFR-TKI as First-line Treatment for Advanced NSCLC with EGFR-positive Mutation Patients: A Systematic Review**
S. Chen¹, E. Marcella², B. Susanto², J. Tandiono¹, R. Heriyanto², F. Wijovi², A. Tancherla², A. Kurniawan³, ¹UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ²Faculty of Medicine Pelita Harapan University, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID
- 12:00 - 12:00 **152P - Effect of Online Continuing Education On Oncologists Knowledge Regrading Resistance To EGFR TKIs In NSCLC**
N. Dorkhom¹, A. Furedy², P. Chen³, ¹Medscape, Naarden, NL, ²Medscape, Atlanta, US, ³Medscape, New York, US

- 12:00 - 12:00 **153P - Real-world study of NSCLC with EGFR Exon 20 insertions**
P. Christopoulos¹, C. Grohé², F. Griesinger³, L. Brückner⁴, R.F. Falkenstern-Ge⁵, J. Krisam⁶, M. Wermke⁷, D. Misch⁸, B. Hackanson⁹, M. Faehling¹⁰, A. Tufman¹¹, M. Janning¹², C. Schulz¹³, M. Reck¹⁴, J.-L. Hong¹⁵, H.M. Lin¹⁵, A. Stenzinger¹⁶, M. Thomas¹⁷, ¹Thoraxklinik Heidelberg and Translational Research Center Heidelberg, Heidelberg, DE, ²Evangelische Lungenklinik, Berlin, DE, ³Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, DE, ⁴Thoraxklinik, University Hospital Heidelberg, Heidelberg, DE, ⁵Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, DE, ⁶Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, DE, ⁷Dresden University Hospital, Dresden, DE, ⁸Lungenklinik Heckeshorn, Helios Hospital Emil von Behring, Berlin, DE, ⁹University Medical Center Augsburg, Augsburg, DE, ¹⁰Klinikum Esslingen, Esslingen am Neckar, DE, ¹¹LMU Klinikum der Universität München, Munich, DE, ¹²University Hospital Mannheim and German Cancer Research Center (DKFZ), Mannheim/Heidelberg, DE, ¹³University Hospital Regensburg, Regensburg, DE, ¹⁴Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ¹⁵Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, ¹⁶Institute of Pathology, University Hospital Heidelberg, Heidelberg, DE, ¹⁷University of Heidelberg, Heidelberg, DE
- 12:00 - 12:00 **154P - Intracranial efficacy of Alectinib in ALK-positive NSCLC patients with CNS metastases; A multicenter retrospective study**
Z. Zou¹, P. Xing², X. Hao², Y. Wang², L. Shan³, C. Zhang⁴, X. Song⁵, K. Ma⁶, Z. Liu⁶, G. Dong⁷, J. Li², ¹National Cancer Center, Cancer Hospital, Beijing, CN, ²Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ³Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, CN, ⁴Inner Mongolia People's Hospital, Huhhot, CN, ⁵Shanxi Provincial Cancer Hospital, Taiyuan, CN, ⁶The First Hospital of Jilin University, Changchun, CN, ⁷Tangshan people's hospital, Tangshan, CN
- 12:00 - 12:00 **155P - Predictors of Treatment Response in ALK-Positive Metastatic Non-Small Cell Lung Cancer**
I. Dogan¹, M. Gürbüz², N. Paksoy¹, F. Ferhatoglu¹, S. Vatansever¹, P. Saip¹, A. Demirkazik², A. Aydin¹, ¹Istanbul University Institute of Oncology, Istanbul, TR, ²Ankara University Faculty of Medicine, Ankara, TR
- 12:00 - 12:00 **156P - Outcomes of ROS1 Positive Metastatic Lung Cancer Patients Treated with Crizotinib**
I. Dogan, N. Khanmammadov, N. Paksoy, F. Ferhatoglu, E. Aydin, S. Vatansever, P. Saip, A. Aydin, Istanbul University Institute of Oncology, Istanbul, TR
- 12:00 - 12:00 **157P - Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION Cohort A**
A. Scherz¹, H. Sakai², X. Le³, E. Felip⁴, R. Veillon⁵, M. Garassino⁶, J. Raskin⁷, S. Viteri⁸, J. Mazieres⁹, A. Cortot¹⁰, E. Smit¹¹, M. Thomas¹², P.F. Conte¹³, M. Gottfried¹⁴, C. Britschgi¹⁵, R. Bruns¹⁶, G. Otto¹⁶, A. Johne¹⁶, P. Paik¹⁷, ¹Inselspital, Bern University Hospital, University of Bern, Bern, CH, ²Saitama Cancer Center, Saitama, JP, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴Vall d'Hebron Institute

of Oncology (VHIO), Barcelona, ES, ⁵CHU Bordeaux, service des maladies respiratoires, Bordeaux, FR, ⁶Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁷Antwerp University Hospital (UZA), Edegem, BE, ⁸Dr Rosell Oncology Institute, Dexeus University Hospital, QuironSalud Group, Barcelona, ES, ⁹Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ¹⁰Universite de Lille, Lille, FR, ¹¹Netherlands Cancer Institute, Amsterdam, NL, ¹²University of Heidelberg, Heidelberg, DE, ¹³University of Padova and Oncologia Medica, Padova, IT, ¹⁴Meir Medical Center, Kefar Sava, IL, ¹⁵Comprehensive Cancer Center Zurich, University Hospital Zurich, Zurich, CH, ¹⁶Merck KGaA, Darmstadt, DE, ¹⁷Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, US

- 12:00 - 12:00 **158P - Prevalence and clinical outcomes of MET exon 14 (METex14) skipping in patients with advanced NSCLC: A systematic literature review**
A. Cortot¹, J. Mazieres², A. Gezin³, A. Garcia³, B. Heeg³, B. Pfeiffer⁴, H. Vioix⁴,
¹Universite de Lille, Lille, FR, ²Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ³Ingress-Health, Rotterdam, NL, ⁴Merck KGaA, Darmstadt, DE
- 12:00 - 12:00 **159P - Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: A systematic literature review**
J. Mazieres¹, A. Cortot², A. Gezin³, A. Garcia³, B. Heeg³, B. Pfeiffer⁴, H. Vioix⁴, ¹Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ²Universite de Lille, Lille, FR, ³Ingress-Health, Rotterdam, NL, ⁴Merck KGaA, Darmstadt, DE
- 12:00 - 12:00 **160P - Non-interventional cohort study on patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping in the US**
A. Ryder¹, D. Oksen², A. Vlahiotis³, E. Boutmy², L.A. Dietz³, C. Stroh², A. Johne⁴, M. Walker³, ¹West Cancer Center and Research Institute, Memphis, US, ²Merck KGaA, Darmstadt, DE, ³ConcertAI, Memphis, US, ⁴Merck KGaA, Darmstadt, DE
- 12:00 - 12:00 **161P - Real-world large-scale study of KRAS fusions in Chinese non-small-cell lung cancer patients: A multicenter study (Yangtze River Delta Lung Cancer Cooperation Group-002)**
D. Wang¹, W.-X. Wang², C. Xu³, J.-Y. Chen¹, Y.-C. Zhu⁴, H. Wang⁵, G.-H. Yu⁶, H.-J. Feng⁷, B.-B. Song⁸, L.-P. Wang⁹, W. Zhuang³, M.-Y. Fang², Q. Wang¹⁰, G.-S. Wang¹¹, Y. Song¹, S. Lu¹², ¹Jinling Hospital, Nanjing University School of Medicine, Nanjing, CN, ²Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, CN, ³Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁴Zhejiang Rongjun Hospital, Jiaxing, CN, ⁵the Fifth Medical Center, General of PLA, Beijing, CN, ⁶Zhejiang Mingzhou Hospital, Huzhou, CN, ⁷Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, CN, ⁸The Affiliated Hospital of Jiaxing University, Jiaxing, CN, ⁹Baotou Cancer Hospital, Baotou, CN, ¹⁰Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, CN, ¹¹Xinqiao Hospital of Third Military Medical University, Chongqing, CN, ¹²Shanghai Chest Hospital, Shanghai, CN
- 12:00 - 12:00 **162P - Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib**

V. Moreno¹, J. Lin², J. Patel³, U. Lassen⁴, B. Solomon⁵, L. Rosen⁶, S. Leyvraz⁷, D.S.W. Tan⁸, G. Beckmann⁹, J.A. Reeves¹⁰, M. Rudolph⁹, J. Wierzbinska⁹, L. Dima¹¹, N. Brega¹⁰, S. Kumar¹², A. Drilon¹³, ¹START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, ES, ²Massachusetts General Hospital and Harvard Medical School, Boston, US, ³Northwestern University, Chicago, US, ⁴Rigshospitalet, Copenhagen, DK, ⁵Sir Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, AU, ⁶UCLA Division of Hematology-Oncology, Santa Monica, US, ⁷Charité - Universitätsmedizin Berlin, Berlin, DE, ⁸National Cancer Centre Singapore, Singapore, SG, ⁹Bayer AG Pharmaceuticals, Berlin, DE, ¹⁰Bayer HealthCare Pharmaceuticals, Whippany, US, ¹¹Bayer HealthCare Pharmaceuticals, Inc., Basel, CH, ¹²Oregon Health & Science University, Portland, US, ¹³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US

12:00 - 12:00

163P - Circulating tumour (ct) DNA Next Generation Sequencing (NGS) in UK advanced non small cell lung cancer (aNSCLC) patients (pts)

W. Cui¹, C. Milner-Watts¹, H. Lyons¹, N. Yousaf¹, A. Minchom¹, J. Bhosle¹, M. Davidson¹, S. Scott², I. Faull², R. Nagy², M. O'Brien³, S. Popat⁴, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²Guardant Health Inc., Redwood City, US, ³The Royal Marsden Hospital - NHS Foundation Trust; Imperial College London, London, GB, ⁴The Royal Marsden Hospital - NHS Foundation Trust; Imperial College London; Institute of Cancer Research, London, GB

12:00 - 12:00

164P - Rapid liquid biopsy genotyping in NSCLC patients

P. Sathyanarayan¹, H. Sloane², D. Edelstein², F. Jones², J. Preston², S. Wu¹, J. Los¹, F. Holtrup², H. Quinn², D. Feller-Kopman¹, ¹Johns Hopkins University School of Medicine, Baltimore, US, ²Sysmex Inostics, Inc., Baltimore, US

12:00 - 12:00

165P - Baseline circulating Myeloid-Derived Suppressor Cells correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in advanced Non-Small Cell Lung Cancer patients treated with Immune Checkpoint Inhibitors

J. García Sánchez¹, M. Benet², L. Cordon², M. Piqueras², J. Garde-Noguera³, M. De Julian⁴, L. Gonzalez-Castillo², D. Lorente⁵, N. Piera³, M.C. Gomez-Soler³, V. Ruiz², J. Carretero⁶, A. Sanchez-Hernandez⁵, O. Juan-Vidal⁷, A. Lahoz², ¹Hospital Arnau de Vilanova, Valencia, ES, ²Instituto de Investigación Sanitaria La Fe, Valencia, ES, ³Hospital Arnau de Vilanova, València, ES, ⁴Hospital Universitario Doctor Peset, Valencia, ES, ⁵Hospital Provincial de Castellón, Castellón de la Plana, ES, ⁶Universidad de Valencia, Valencia, ES, ⁷Hospital Universitari I Politècnic La Fe, Valencia, ES

12:00 - 12:00

166P - First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A three arms, prospective study

B. Han, T. Chu, W. Zhang, B. Han, X. Zhang, C. Shi, R. Zhong, H. Zhong, W. Wang, A. Gu, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00

167P - Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer (aNSCLC): a pooled analysis of 6 randomized trials

P. Gargiulo¹, R. Di Liello², L. Arenare¹, C. Gridelli³, A. Morabito¹, F. Ciardiello⁴, V. Gebbia⁵, P. Maione³, A. Spagnuolo³, G. Palumbo¹, G. Esposito¹, C.M. Della Corte², F. Morgillo², G. Mancuso⁵, A. Gravina¹, C. Schettino¹, M. Di Maio⁶, C. Gallo², F. Perrone¹,

M.C. Piccirillo¹, ¹Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, IT, ²Università degli studi della Campania Luigi Vanvitelli, Napoli, IT, ³Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT, ⁴Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁵Università di Palermo, Palermo, IT, ⁶University of Turin, Ordine Mauriziano Hospital, Torino, IT

- 12:00 - 12:00 **168P - Changes in cfDNA levels in squamous non-small cell lung cancer with chemotherapy : correlation with symptom scores and radiological responses**
N. Singh, N. Ravi, A. Bal, M. Garg, R. Kapoor, K. Prasad, PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN
- 12:00 - 12:00 **169P - BEPACT Lung: A prospective, multicenter, non-interventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer (NSCLC).**
A. Sibille¹, F. Bustin², C. Compere³, K. Cuppens⁴, S. Coulon⁵, L. Decoster⁶, L. Decoster⁷, I. Demedts⁸, K. Deschepper⁹, A. Janssens¹⁰, S. Ocak¹¹, C. Oyen¹², K. Pat¹³, T. Pieters¹⁴, V. Pruniau⁵, J. Vansteenkiste¹⁵, ¹Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ²Centre Hospitalier Régional de la Citadelle, Liège, BE, ³Delta Hospital - Chirec, Brussels, BE, ⁴Virga Jesse Ziekenhuis, Hasselt, BE, ⁵MSD Belgium BVBA/SPRL, Woluwe-Saint-Lambert, BE, ⁶Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, BE, ⁷AZ Turnhout - Campus St. Elisabeth, Turnhout, BE, ⁸AZ Delta Campus Wilgenstraat, Roeselare, BE, ⁹AZ Nikolaas Hospital, St Niklaas, BE, ¹⁰University Hospital Antwerp (UZA), Edegem, BE, ¹¹CHU UCL Namur - Site Godinne, Yvoir, BE, ¹²University Hospitals KU Leuven, Leuven, BE, ¹³Jesse Ziekenhuis - Campus Virga Jesse, Hasselt, BE, ¹⁴Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ¹⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 12:00 - 12:00 **170P - Predictors for cancer-related fatigue among patients with advanced lung cancer attending palliative care department: A Prospective observational study**
C. Patil¹, S. Atreya², ¹Kolhapur Cancer Centre, Kolhapur, IN, ²Tata Medical Center, Kolkata, IN
- 12:00 - 12:00 **171P - Association between patient-reported toxicity and health-related quality of life in (locally-) advanced non-small cell lung cancer**
L. Van Der Weijst, V. Surmont, W. Schrauwen, Y. Lievens, Ghent University Hospital, Gent, BE
- 12:00 - 12:00 **172P - Anlotinib as Treatment for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis on Overall Survival and Progression Free Survival**
B. Susanto¹, E. Marcella¹, S. Chen², R. Heriyanto¹, J. Tandiono², F. Wijovi¹, A. Tancherla¹, A. Kurniawan³, ¹Faculty of Medicine Pelita Harapan University, Tangerang, ID, ²UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID
- 12:00 - 12:00 **173P - Evaluating the content validity, clarity, and relevance of the PROMIS-physical function (PROMIS-PF)-8C and non-small cell lung cancer (NSCLC)-Symptom assessment questionnaire (NSCLC-SAQ) in adults with epidermal growth factor receptor (EGFR)-mutated NSCLC**

K. Liu¹, M. Horn², S. Mathias³, H. Colwell³, T. Li¹, P. Mahadevia¹, R. Pierson¹, ¹Janssen Pharmaceuticals, Raritan, US, ²ICAN, International Cancer Advocacy Network, Phoenix, US, ³Health Outcomes Solutions, Winter Park, US

- 12:00 - 12:00 **174P - Safety and efficacy of anlotinib plus docetaxel in advanced non-small-cell lung cancer patients after failure of first-line chemotherapy: recent results from the ongoing phase II study (ALTER-L024).**
B. Jin¹, G. Wang², Y. Zhang¹, R. Wu³, J. Chen⁴, Y. Dong⁵, L. Peng¹, ¹The First Affiliated Hospital of China Medical University, Shenyang, CN, ²The Affiliated Zhongshan Hospital of Dalian University, Dalian, CN, ³Shengjing Hospital of China Medical University, Shenyang, CN, ⁴The Second Affiliated Hospital of Dalian Medical University, Dalian, CN, ⁵Anshan Tumor Hospital, Anshan, CN
- 12:00 - 12:00 **175P - Incidence and treatment outcomes of Brain Metastasis in Advanced Non-Small Cell Lung Cancer at presentation - An Experience from South India**
K. Kaliyamurthi, Madras Medical College, Chennai, IN
- 12:00 - 12:00 **176P - Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC)**
M. Vitorino, T. Tomás, S. Almeida, M. Silva, Hospital Professor Doutor Fernando Fonseca EPE (Hospital Amadora/Sintra), Lisbon, PT
- 12:00 - 12:00 **177P - Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: a retrospective multi-institutional analysis**
S. Takemoto¹, T. Suyama¹, N. Honda¹, Y. Umeyama¹, Y. Dostu¹, G. Hiroshi¹, H. Yamaguchi², M. Fukuda², H. Mukae², ¹Nagasaki University Hospital, Nagasaki City, JP, ²Nagasaki University Hospital, Nagasaki, JP
- 12:00 - 12:00 **178P - Neutrophil Lymphocyte Ratio (NLR) Kinetics as a Biomarker of Treatment Response and Outcome**
S. Subramaniam¹, S. Malwinder², ¹UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, ²University Malaya Medical Center, Kuala Lumpur, MY
- 12:00 - 12:00 **179P - Efficacy and safety of extended-interval dosing strategy of immune checkpoints inhibitors during COVID-19 outbreak: experience from a single center**
C. Pierre¹, T. Goter¹, C. Agar¹, S. Luzi¹, H. Lena², Y. Le Guen¹, C. Ricordel¹, ¹CHU Rennes, RENNES, FR, ²CHU de Pontchaillou, Rennes, FR
- 12:00 - 12:00 **180P - Incidence of brain metastases (BM) in newly diagnosed stage 4 NSCLC during COVID-19**
W. Cui¹, C. Milner-Watts¹, S. Saith¹, J. Bhosle¹, A. Minchom¹, M. Davidson¹, S. Page¹, I. Locke¹, N. Yousaf¹, S. Popat², M. O'Brien³, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²The Royal Marsden Hospital - NHS Foundation Trust; Imperial College London; Institute of Cancer Research, London, GB, ³The Royal Marsden Hospital - NHS Foundation Trust; Imperial College London, London, GB

- 12:00 - 12:00 **181P - Multicenter real world study (RWS) on efficacy and early discontinuation predictors in Non-Small-Cell Lung Cancer (NSCLC) patients (pts) receiving nivolumab.**
- G. Pasello¹, A. Bortolami², S. Tognazzo², G. Crivellaro², A. Torchia¹, M. Lorenzi³, J. Menis¹, S. Frega⁴, L. Bonanno⁵, V. Guarneri², P.F. Conte⁶, ¹University of Padova, Padova, IT, ²Istituto Oncologico Veneto IRCCS, Padova, IT, ³University of Padua, Padua, IT, ⁴Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁵Istituto Oncologico Veneto IOV - IRCCS, Padova, IT, ⁶University of Padova and Oncologia Medica, Padova, IT
- 12:00 - 12:00 **182P - Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: a retrospective comparative cohort study**
- E. Marin¹, C. Teixido¹, A. Arcocha¹, S. Castillo², R. Reyes¹, N. Viñolas¹, L. Mezquita³, S. Muñoz², D. Martinez¹, P. Jares¹, N. Reguart¹, ¹Hospital Clinic of Barcelona, Barcelona, ES, ²Hospital General of Granollers, Granollers, ES, ³Hospital Clinic i Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **183P - Pulmonary carcinosarcomas: a retrospective analysis of cases from cancer registry**
- M. Puchinskaya¹, L. Levin², ¹Minsk City Clinical Oncologic Dispensary, Minsk, BY, ²N. N. ALEXANDROV NATIONAL CANCER CENTRE OF BELARUS, Lesnoy, BY
- 12:00 - 12:00 **184P - Bone-targeted agents (BTA) improve survival in advanced non-small-cell-lung-cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)**
- S. Manglaviti¹, G. Galli¹, M. Bini¹, A. Labianca¹, E. Zecca¹, M. Brambilla¹, M. Occhipinti¹, C. Proto¹, A. Prelaj¹, D. Signorelli¹, A. De Toma¹, G. Viscardi¹, T. Beninato¹, E. Zattarin¹, M. Ganzinelli¹, F. De Braud¹, M. Garassino², G. Lo Russo¹, R. Ferrara¹, ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 12:00 - 12:00 **186TiP - An open-label, dose escalation, Phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with Non-small cell lung cancer (NSCLC)**
- J. Bennouna¹, A. Sibille², C. Debruyne³, B. Colinet⁴, I. Demedts⁵, S. Derijcke⁶, L. Greillier⁷, J. Jürgens⁸, H. Lena⁹, D. Moro-Sibilot¹⁰, M. Perol¹¹, X. Quantin¹², N. Reinmuth¹³, M. Sebastian¹⁴, M. Genin¹⁵, J. Plumas¹⁶, J. Vansteenkiste¹⁷, ¹University Hospital of Nantes, Nantes, FR, ²Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ³PDC*line Pharma SA, Liège, BE, ⁴Grand Hôpital de Charleroi (GHdC), Charleroi, BE, ⁵AZ Delta Campus Wilgenstraat, Roeselare, BE, ⁶AZ Groeninge Hospital, Kortrijk, BE, ⁷Aix Marseille University, APHM, Marseille, FR, ⁸Kliniken der Stadt Köln gGmbH, Koeln, DE, ⁹CHU de Pontchaillou, Rennes, FR, ¹⁰CHU de Grenoble, La Tronche, FR, ¹¹Léon Bérard Cancer Center, Lyon, FR, ¹²ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹³Asklepios-Fachklinikum, Gauting, DE, ¹⁴Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ¹⁵PDC*line Pharma SAS, La Tronche, FR, ¹⁶PDC*Line Pharma, La Tronche, FR, ¹⁷University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

- 12:00 - 12:00 **187TiP - Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors**
S. Gettinger¹, H. Kluger¹, A. Schoenfeld², A. Betof Warner³, K. He⁴, A. Sukari⁵, S. Thomas⁶, B. Doger De Spéville⁷, S. Lee⁸, S. Haefliger⁹, Z. Goldberg¹⁰, A. Cacovean¹⁰, R. Fiaz¹⁰, G. Chen¹⁰, M. Jagasia¹⁰, F. Graf Finckenstein¹⁰, M. Fardis¹⁰, A. Jimeno¹¹, ¹Yale Cancer Center, Yale University School of Medicine, New Haven, US, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴James Cancer Center, The Ohio State University, Columbus, US, ⁵Barbara Ann Karmanos Cancer Center, Wayne State University, Detroit, US, ⁶University of Florida Health Cancer Center at Orlando Health, Orlando, US, ⁷University Hospital Fundacion Jimenez Diaz, Madrid, ES, ⁸Seattle Cancer Care Alliance, University of Washington, Seattle, Seattle, US, ⁹Inselspital, Universitätsspital Bern, Bern, CH, ¹⁰Iovance Biotherapeutics, Inc., San Carlos, US, ¹¹University of Colorado Comprehensive Cancer Center, Aurora, US
- 12:00 - 12:00 **188TiP - A phase 2 multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)**
E. Massarelli¹, Z. Goldberg², A. Cacovean², B. Yadav², G. Chen², M. Jagasia², F. Graf Finckenstein², M. Fardis², A. Sukari³, ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Iovance Biotherapeutics, Inc., San Carlos, US, ³Barbara Ann Karmanos Cancer Center, Wayne State University, Detroit, US
- 12:00 - 12:00 **189TiP - Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC**
T. Wehler¹, B. Wehler¹, H. Atmaca-Dirik¹, C. Schulz², C. Grohé³, J. Topsch⁴, A. Ehrlich⁴, ¹Evangelisches Krankenhaus Hamm & Lungenklinik Hemer, Hamm, DE, ²University Hospital Regensburg, Regensburg, DE, ³Evangelische Lungenklinik, Berlin, DE, ⁴Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz, Mainz, DE
- 12:00 - 12:00 **190TiP - Anlotinib plus carboplatin/pemetrexed in treatment-naïve advanced non-squamous NSCLC: An open-label, randomized, phase II study**
R. Guo, W. Gao, J. Li, Y. Liu, X. Liu, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN
- 12:00 - 12:00 **191TiP - Accelerating Lung Cancer Diagnosis through Liquid Biopsy**
M. García Pardo De Santayana¹, K. Czarnecka², T. Waddell³, T. Stockley⁴, J. Law¹, L. Le¹, P. Pal⁴, P. Rogalla², D. Kelly¹, N. Leigh¹, ¹University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²Toronto General Hospital, TORONTO, CA, ³Toronto General Hospital, Toronto, CA, ⁴University Health Network, Toronto, CA
- 12:00 - 12:00 **192TiP - Radiological morphological (MF) and radiomic features (RF) of brain metastases in oncogene-addicted advanced non-small cell lung cancer (NSCLC) patients: diagnostic implications and prognostic role (BRAIN Lung study).**
S.E. Rebutuzzi¹, L. Barletta², E. Rosso², M. Maddalo³, A. Signori⁴, F. Catalano², M. Grassi⁵, M. Tagliamento⁶, G. Rossi⁷, M.G. Dal Bello², G. Mazzaschi³, E. Barabino⁸, A. Fedeli⁴, M.

Doni², M. Tiseo⁹, C. Genova⁶, ¹Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, IT, ²IRCCS Ospedale Policlinico San Martino, Genova, IT, ³University Hospital of Parma, Parma, IT, ⁴University of Genova, Genova, IT, ⁵IRCCS Ospedale Policlinico San Martino of Genova, Genova, IT, ⁶; Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, IT, ⁷; Ospedale "Padre Antero Micone", Genova, IT, ⁸Ospedale Santa Corona, Pietra Ligure, IT, ⁹Department of Medicine and Surgery, University of Parma, Parma, IT

12:00 - 12:00 **Metastases to and from the lung**

12:00 - 12:00 **193P - Long-term survival in non-small cell lung cancer patients with metachronous brain-only oligorecurrence who underwent definitive treatment**

H. Kim¹, S. Park², H.A. Jung³, J.-M. Sun², S.-H. Lee², J.S. Ahn², K. Park⁴, M.-J. Ahn⁵, ¹Samsung Medical Center, Seoul, US, ²Samsung Medical Center, Seoul, KR, ³Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Sungkyunkwan University School of Medicine, Seoul, KR

12:00 - 12:00 **194P - The clinicopathological characteristics and proteomics analysis of highly aggressive T1N2M0 NSCLC patients**

X. Lei, Tianjin Medical University General Hospital, Tianjin, CN

12:00 - 12:00 **195P - Brain and heart in cancer patients; Population-based study**

M. Safi¹, M. Al-Radhi², R. Kanesvaran³, D. Trapani⁴, S. Mazher⁵, M. Alnusaiif⁶, A. Aldanakh¹, S. Baldi⁷, Y. Moeed⁸, H. Al-Dubai⁹, X. Sun¹⁰, X. Shan¹, M. Ameen⁷, J. Liu¹, ¹First Affiliated Hospital of Dalian Medical University, Dalian, CN, ²Second Affiliated Hospital of Dalian Medical University, Dalian, CN, ³National Cancer Center Singapore, Singapore, SG, ⁴Istituto Europeo di Oncologia, Milan, IT, ⁵The University of Texas Southwestern Medical Center, Texas, US, ⁶First Affiliated Hospital of Dalian Medical University, Dalian city, CN, ⁷Dalian Medical University, Dalian, CN, ⁸Guangxi Medical University, Nanning, CN, ⁹Eastern Cost Medical and Teaching Compound, Hodaidah, YE, ¹⁰Second Affiliated Hospital of Dalian Medical University, Dalian city, CN

12:00 - 12:00 **Mesothelioma**

12:00 - 12:00 **196P - A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): preliminary results.**

R. Di Liello¹, C.M. Della Corte¹, V. Ciaramella¹, A. Insa², D. Compañ-Quilis², G. Alonso², R. Borrás², G. Viscardi³, N. Zanaletti¹, F. Sparano⁴, I. Cozzolino¹, M. Montella¹, G. Vicidomini¹, I. Pastor-Escartín², M. Santini¹, R. Franco¹, F. Ciardiello⁴, P. Martín-Martorell², F. Morgillo¹, ¹Università degli studi della Campania Luigi Vanvitelli, Napoli, IT, ²Hospital Clínico Universitario de Valencia, Valencia, ES, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

- 12:00 - 12:00 **197P - Development of a core outcome set for clinical studies of the invasive management of malignant pleural mesothelioma: The COSi-meso initiative**
K. Chandarana, A. Gkikas, E. Caruana, A. Nakas, Glenfield Hospital - University Hospitals of Leicester NHS Trust, Leicester, GB
- 12:00 - 12:00 **198P - Analysis of efficacy of immunotherapy according to histology in malignant pleural mesothelioma (MPM) patients**
S. Cedres¹, J.D. Assaf¹, P. Iranzo¹, A. Callejo¹, N. Pardo¹, A. Navaro¹, A. Martinez-Marti¹, H. Bote², D. Marmolejo¹, J. Lostes¹, V. Monton¹, J. Gonzalo¹, A. Pedrola¹, E. Felip³, ¹Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 12:00 - 12:00 **199P - Clinical and Epidemiological characteristics of patients with Pleural mesothelioma in the United States**
D. El-Habashy, Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG
- 12:00 - 12:00 **200P - Prognostic factors in malignant pleural mesothelioma - a multicentric study**
M. Baptista¹, J. Barata¹, G. Fernandes², S. Saleiro³, M. Souto Moura³, A. Magalhães², M.J. Valente¹, M.L.S. Valente¹, ¹Centro Hospitalar Cova da Beira, Covilha, PT, ²Centro Hospitalar São João, Porto, PT, ³Instituto Português de Oncologia Porto, Porto, PT
- 12:00 - 12:00 **201P - Inequality in mesothelioma care in the North East of England**
A. Aujayeb, Private Sector, Quatre Bornes, MU
- 12:00 - 12:00 **202P - Indwelling pleural catheter removals in a large volume centre in the North East of England**
A. Aujayeb, Private Sector, Quatre Bornes, MU
- 12:00 - 12:00 **General interest**
- 12:00 - 12:00 **204P - Immune-related Adverse Events (irAEs) as a predictor of response to Immunotherapy in patients with Lung Cancer**
M.V. Sanchez Becerra¹, R. Martinez-Cabañes¹, A. Gonzalez-Lopez¹, E. Zhan-Zhou¹, V. Sotelo¹, M. Esteban¹, T. Robles¹, J.C. Camara¹, A. Cardena¹, S. Hernando¹, A. Hurtado², D. Moreno¹, C. Olier¹, X. Mielgo Rubio¹, ¹Hospital Universitario Fundación Alcorcón, Alcorcon, ES, ²HUFA Hospital Universitario Fundación Alcorcon, Alcorcon, ES
- 12:00 - 12:00 **205P - Impact of UK Covid-19 Pandemic Cancer Guidelines on Treatment Decisions for Thoracic Malignancies**
J. Morton-Gittens¹, N. Pipalia¹, K. Thippu Jayaprakash², ¹The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, GB, ²Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB

- 12:00 - 12:00 **206P - Impact of COVID-19 pandemic in the diagnosis of lung cancer in Portugal**
M. Leitão¹, A. Teixeira², M. Neves², I. Azevedo², C. Vieira², ¹Instituto Portugues de Oncologia - Porto, Porto, PT, ²IPO Porto, Porto, PT
- 12:00 - 12:00 **207P - Lung Immune Prognostic Index and Survival in Patient with Non-Small Cell Lung Cancer: A Systematic Review**
R. Heriyanto¹, C. Chrystelle², A. Hadisurya², F. Tandy², M. Suciningtias², A. Kurniawan³, ¹Faculty of Medicine Pelita Harapan University, Tangerang, ID, ²UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ³Pelita Harapan University, Tangerang, ID
- 12:00 - 12:00 **208P - Safety and efficacy of immune checkpoint inhibitors in NSCLC patients with autoimmune disease: A UK tertiary cancer centre experience**
P. Sawhney, G. Patel, D. Ohana, M. Luong, Y.N.S. Wong, A. Lee, S.-M. Lee, M. Forster, University College London Hospitals NHS Trust, London, GB
- 12:00 - 12:00 **209P_PR - Understanding patient experience in Europe: the first Global Lung Cancer Coalition Patient Experience Survey**
V. Beattie¹, W. Boerckel², M. Rigney³, K. O'Hagan⁴, M. Hennink⁵, J. Fox⁶, ¹Lung Cancer Nursing UK, Solihull, GB, ²Cancer Care, New York, US, ³GO2Foundation, Washington, US, ⁴Irish Cancer Society, Dublin, IE, ⁵Patient, NotApplicable, NL, ⁶Roy Castle Lung Cancer Foundation, Liverpool, GB
- 12:00 - 12:00 **210P - Lung Cancer: 10-Year Survival**
O. Kshivets, Roshal Hospital, Roshal, Moscow, Roshal, RU
- 12:00 - 12:00 **211P - Prior Antibiotic Use in Immunotherapy treated patients - the experience of a community hospital**
M. Vitorino, M. Batista, T. Tomás, S. Almeida, R. Freitas, M. Silva, Hospital Professor Doutor Fernando Fonseca EPE (Hospital Amadora/Sintra), Lisbon, PT
- 12:00 - 12:00 **212P_PR - Language and Understanding: the complexity of insight in cancer care**
T. Martin¹, D. O'Doherty¹, C. Mattisa¹, T. Byrne¹, R. Keogh¹, C. Murphy¹, P. Bredin¹, S. Devanney¹, P. Morris¹, B. Hennessy¹, L. Grogan¹, O. Breathnach², R. O'Dwyer¹, ¹Beaumont Hospital, Dublin, IE, ²Thoraxklinik, University Hospital Heidelberg, Heidelberg, DE
- 12:00 - 12:00 **213P - Incidence of venous thromboembolic events in lung cancer patients receiving immunotherapy: a single institution experience**
L. Gutiérrez Sainz, P. Cruz Castellanos, D. Sanchez Cabrero, O. Higuera Gomez, J. De Castro Carpeno, Hospital Universitario La Paz, Madrid, ES
- 12:00 - 12:00 **214P - The role of USS guided biopsy in the investigation of lung cancer**
A. Aujayeb¹, C. Storey², P. Narkhede², E. Hill², M. Carling², ¹Private Sector, Quatre Bornes, MU, ²Northumbria Healthcare NHS Foundation Trust, Newcastle, GB



- 12:00 - 12:00 **215P - The feasibility of day case thoracoscopy**
A. Aujayeb¹, E. Hill², ¹Private Sector, Quatre Bornes, MU, ²Northumbria Healthcare NHS Foundation Trust, Newcastle, GB
- 12:00 - 12:00 **216P - COMMD1 in non-small cell lung cancer: a novel DNA repair protein as a therapeutic target and diagnostic biomarker**
A. Suraweera¹, P. Duijf¹, M. Tang¹, C. Jekimovs¹, K. Schrobback¹, C. Liu², M. Adams¹, D. Richard¹, K. O'Byrne¹, ¹Queensland University of Technology, Brisbane, AU, ²QIMR Berghofer Medical Research Institute, Brisbane, AU
- 12:00 - 12:00 **217P - Circulating microRNA21 and microRNA126: Diagnostic, Prognostic Value and Multivariate Analysis in Non-Small-Cell Lung Cancer**
A. Alhanafy¹, S. Soliman², A. Abdelaleem³, A. Abo Elhaded⁴, M. Assar⁴, R. Ibrahim², ¹MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, ²MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, ³College of Medicine, Qassim University, Qassim, SA, ⁴Faculty of science - Menoufia University, shebeen elkom, EG
- 12:00 - 16:15 **218P - Clinical characteristics and treatment outcomes in lung cancer patients with FGFR genes alterations**
J. Torres Jimenez, J. Esteban Villarrubia, E. Vida Navas, J.J. Soto Castillo, L. Sanz Gómez, I. Orejana Martín, P. Alvarez Ballesteros, J. Pozas Pérez, M. San Román Gil, V. Albarrán Fernández, J. Chamorro Pérez, D.I. Rosero Rodríguez, A. Gómez Rueda, E. Corral De La Fuente, Y. Lage, A. Santón, A. Benito Berlinches, M. Lario, M.E. Olmedo García, P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

25.03.2021

09:10 - 09:45 Opening session and Heine H. Hansen Award lecture 2021 Channel 1
 Moderation: E. Felip¹, D. Planchard², ¹Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ²Institut Gustave Roussy, Villejuif, FR

09:10 - 09:15 **Welcome by the Scientific Co-Chairs**

09:15 - 09:20 **Introduction to the Heine H. Hansen Award 2021**
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

09:20 - 09:45 **Drop by drop makes a Lake: 30 years of progress in lung cancer**
J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

10:00 - 11:00 Mesothelioma: Will I-O shape the future? Channel 3

10:00 - 10:15 **Molecular risk factors and predictive biomarkers**
G. Zalcman, Hopital Bichat Claude Bernard, Paris, FR

10:15 - 10:30 **What is the standard of care in front-line and beyond?**
A. Tsao, The University of Texas M. D. Anderson Cancer Center, Houston, US

10:30 - 10:45 **Indication for lung-sparing radiotherapy**
A. Rimner, Memorial Sloan Kettering Cancer Center, New York, US

10:45 - 11:00 **Surgery**
E. Lim, Royal Brompton Hospital - Royal Brompton and Harefield NHS Foundation Trust, London, GB

10:00 - 11:00 Novel therapeutic approaches: Exciting times in lung cancer Channel 2

10:00 - 10:15 **Antibody drug conjugates**
D. Planchard, Institut Gustave Roussy, Villejuif, FR

10:15 - 10:30 **Bi-specific and tri-specific Ab**
B.C. Cho, Yonsei University, Seoul, KR

10:30 - 10:45 **Engineered for success: Immunocytokines and radioimmunotherapy**
E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

10:45 - 11:00 **New approaches in supportive care**
K. Jordan, University of Heidelberg, Heidelberg, DE

10:00 - 11:00 Lung cancer screening: The end of the beginning Channel 1

10:00 - 10:15 **Nelson and NSLT: Are the results similar?**
J. Field, The University of Liverpool, Liverpool, GB

10:15 - 10:30 **Implementation of screening programmes**
S. Couraud, CHU Lyon, Lyon, FR

10:30 - 10:45 **Novel screening approaches**
J. Van Meerbeeck, UZA - University Hospital Antwerp, Edegem, BE

10:45 - 11:00 **Optimal management of lesions discovered at screening**
G. Veronesi, IRCCS Ospedale San Raffaele, Milan, IT

11:15 - 12:35 Optimal management of patients with PDL1-high advanced NSCLC Channel 1

Moderation: F. Cappuzzo¹, L. Landi², ¹Ospedale Santa Maria Delle Croci, Istituto Nazionale Tumori "Regina Elena", Rome, IT, ²Ospedale Santa Maria delle Croci, Ravenna, IT

11:15 - 11:20 **Presentation of case: Monotherapy or chemoimmunotherapy in PD-L1>50%?**
L. Landi, Ospedale Santa Maria delle Croci, Ravenna, IT

11:20 - 11:35 **Options in patients with brain metastases**
O. Gautschi, Luzerner Kantonsspital, Luzern, CH

11:35 - 11:50 **Role of chemo-free combinations**
S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, US

11:50 - 12:05 **Role of chemo-IO combinations**
F. Cappuzzo, Istituto Nazionale Tumori "Regina Elena", Rome, IT

12:05 - 12:20 **Role of single agent immunotherapy**
M.R. Garcia Campelo, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

12:20 - 12:35 **Q&A and live discussion**
A. Speakers, , CH

- 11:15 - 12:35 The eternal debate in stage III Channel 2**
Moderation: A. Brunelli¹, I. Browne², ¹St. James's University Hospital Leeds, Leeds, GB, ²Mater University Hospital, Dublin, IE
- 11:15 - 11:20 **Presentation of case**
I. Browne, Mater University Hospital, Dublin, IE
- 11:20 - 11:35 **What is the best local treatment? Surgery**
G. Massard, University of Luxemburg, LU
- 11:35 - 11:50 **What is the best local treatment? Radiation therapy**
M. Werner-Wasik, Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US
- 11:50 - 12:05 **Don't forget the systemic treatment**
L. Coate, University Hospital Limerick, Limerick, IE
- 12:05 - 12:20 **IO in stage III**
J. Lee, UCLA - David Geffen School of Medicine, Los Angeles, US
- 12:20 - 12:35 **Q&A and live discussion**
A. Speakers, , CH
- 11:15 - 12:35 YO Vesalius Talk: How to run translational research studies in lung cancer? Where to start? Channel 3**
Moderation: J. Lim¹, A.S. Berghoff², ¹ Manchester, GB, ² Vienna, AT
- 11:15 - 11:25 **Welcome and Young Oncologist perspective**
J. Lim¹, A.S. Berghoff², ¹ Manchester, GB, ² Vienna, AT
- 11:25 - 11:31 **Your perspective and personal story**
J. Wolf, Köln, DE
- 11:31 - 11:37 **Your perspective and personal story**
L. Paz-Ares, Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES
- 11:37 - 11:43 **Your perspective and personal story**
F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB
- 11:43 - 12:35 **Q&A and live discussion**
A. Speakers, , CH

12:50 - 14:20 MSD - Defining the standard of care in lung cancer Channel 1

Moderation: L. Paz-Ares, Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

12:50 - 12:55 Welcome and Introduction

L. Paz-Ares, Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

12:55 - 13:10 Can we turn lung cancer into a chronic disease?

M. Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE

13:10 - 13:35 Selecting the right treatment for the right patient: A case study discussion with Prof. Alessandra Curioni, Prof. Martin Reck and Prof. Luis Paz-Ares

A. Curioni¹, M. Reck², L. Paz-Ares³, ¹University Hospital Zurich, Zurich, CH, ²Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ³Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

13:35 - 13:50 A look into the future of NSCLC: Emerging treatment options

L. Paz-Ares, Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

13:50 - 14:20 Live Q&A

A. Speakers, , CH

14:20 - 14:20 Meeting close

L. Paz-Ares, Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

12:50 - 14:20	Novartis - Early treatment decisions in NSCLC: A debate on best practices	Channel 2
	Moderation: M. Thomas, University of Heidelberg, Heidelberg, DE	
12:50 - 12:55	Welcome and introduction <u>M. Thomas</u> , University of Heidelberg, Heidelberg, DE	
12:55 - 13:10	The path to diagnosis in patients with NSCLC <u>M. Thomas</u> , University of Heidelberg, Heidelberg, DE	
13:10 - 13:50	Navigating through treatment decisions in NSCLC. Virtual panel debate, moderated by Prof. Michael Thomas together with the participation of Prof. Rosario Garcia Campelo and Prof. Thomas Newsom-Davis <u>M.R. Garcia Campelo</u> ¹ , T. Newsom-Davis ² , M. Thomas ³ , ¹ Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ² Chelsea and Westminster Hospital NHS Foundation Trust, London, GB, ³ University of Heidelberg, Heidelberg, DE	
13:50 - 14:05	Live Q&A and concluding remarks <u>A. Speakers</u> , , CH	
12:50 - 14:20	Medscape Oncology Global - Advances in oncogene driven metastatic NSCLC: Focusing on EGFR Exon 20 insertions and ALK-Positive NSCLC	Channel 3
	Moderation: M. Perol, Léon Bérard Cancer Center, Lyon, FR	
12:50 - 12:55	Welcome and introduction <u>M. Perol</u> , Léon Bérard Cancer Center, Lyon, FR	
12:55 - 13:15	Keeping up with the development in molecular testing for advanced NSCLC <u>K. Kerr</u> , Aberdeen University Medical School, Aberdeen, GB	
13:15 - 13:35	The patient with an EGFR Exon 20 insertion: Expert insights and recommendations <u>M. Perol</u> , Léon Bérard Cancer Center, Lyon, FR	
13:35 - 13:55	Best practices in managing patients with De Novo ALK-Positive advanced NSCLC <u>R. Califano</u> , The Christie NHS Foundation Trust, University of Manchester, Manchester, GB	
13:55 - 14:15	Panel discussion & live Q&A <u>A. Speakers</u> , , CH	
14:15 - 14:20	Concluding remarks <u>M. Perol</u> , Léon Bérard Cancer Center, Lyon, FR	
14:35 - 15:55	Proffered Paper session	Channel 1

Moderation: F. Cappuzzo¹, J. Brahmer², ¹Ospedale Santa Maria Delle Croci, Istituto Nazionale Tumori "Regina Elena", Rome, IT, ²Oncology, Johns Hopkins Kimmel Cancer Center, Baltimore, US

14:35 - 14:45

960 - Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

C. Zhou¹, S. Ren¹, J. Chen², X. Xu³, Y. Cheng⁴, G. Chen⁵, Y. Pan⁶, Y. Fang⁷, Q. Wang⁸, Y. Huang⁹, W. Yao¹⁰, R. Wang¹¹, X. Li¹², W. Zhang¹³, Y. Zhang¹⁴, S. Hu¹⁵, R. Guo¹⁶, Z. Yang¹⁷, L. Wang¹⁷, ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²Hunan Cancer Hospital, Changsha, CN, ³Northern Jiangsu People's Hospital, Yangzhou, CN, ⁴Jilin Provincial Cancer Hospital, Changchun, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, CN, ⁷Sir Run Run Shaw Hospital Zhejiang University School Of Medicine, Hangzhou, CN, ⁸Henan Cancer Hospital, Zhengzhou, CN, ⁹Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, ¹⁰Sichuan Provincial Cancer Hospital, Chengdu, CN, ¹¹Anhui Chest Hospital, Hefei, CN, ¹²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹³The First Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁴Shaanxi Provincial Cancer Hospital, Xian, CN, ¹⁵Hubei Cancer Hospital, Wuhan, CN, ¹⁶Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ¹⁷Jiangsu Hengrui Medicine Co., Ltd., Shanghai, CN

14:45 - 14:55

970 - First-Line Pembrolizumab Plus Chemotherapy for Patients With Advanced Squamous NSCLC: 3-Year Follow-up From KEYNOTE-407

A. Robinson¹, D. Vicente², A. Tafreshi³, H. Soto Parra⁴, J. Mazieres⁵, I. Cicin⁶, B. Medgyasszay⁷, J. Rodríguez-Cid⁸, I. Okamoto⁹, S.S. Lee¹⁰, R. Ramlau¹¹, V. Vladimirov¹², Y. Cheng¹³, B. Halmos¹⁴, C.-C. Liu¹⁵, P. Schwarzenberger¹⁵, B. Piperdi¹⁵, L. Paz-Ares¹⁶, ¹Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, CA, ²Hospital Universitario Virgen Macarena, Sevilla, ES, ³Wollongong Private Hospital and Wollongong Oncology, Wollongong, AU, ⁴AOU Policlinico Vittorio Emanuele, Catania, IT, ⁵Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ⁶Trakya University, Edirne, TR, ⁷Veszprém Megyei Tüdogyógyintézet Farkasgyepu, Farkasgyepu, HU, ⁸Oncology Center, Medica Sur Hospital, Mexico City, MX, ⁹Kyushu University Hospital, Fukuoka, JP, ¹⁰Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, KR, ¹¹Poznan University of Medical Sciences, Poznan, PL, ¹²State Healthcare Institute, Pyatigorsk Oncology Dispensary, Pyatigorsk, RU, ¹³Jilin Provincial Cancer Hospital, Changchun, CN, ¹⁴Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, US, ¹⁵Merck & Co., Inc., Kenilworth, US, ¹⁶Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

14:55 - 15:05

980 - First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

L. Paz-Ares¹, T.-E. Ciuleanu², M. Cobo Dols³, M. Schenker⁴, B. Zurawski⁵, J. Menezes⁶, E. Richardet⁷, J. Bennouna⁸, E. Felip⁹, O. Juan-Vidal¹⁰, A. Alexandru¹¹, H. Sakai¹², A. Scherpereel¹³, M. Reck¹⁴, S. Lu¹⁵, T. John¹⁶, S. Meadows-Shropshire¹⁷, D. Balli¹⁷, S.

Agrawal¹⁷, D. Carbone¹⁸, ¹Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES, ²Institutul Oncologic Prof. Dr. Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, RO, ³Hospital Regional Universitario de Málaga, IBIMA, Malaga, ES, ⁴SF. Nectarie Oncology Center, Craiova, RO, ⁵Ambulatorium Chemioterapii, Bydgoszcz, PL, ⁶Hospital Nossa Senhora Da Conceição, Porto Alegre, BR, ⁷Instituto Oncológico De Córdoba, Córdoba, AR, ⁸University Hospital of Nantes, Nantes, FR, ⁹Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹⁰Hospital Universitari I Politècnic La Fe, Valencia, ES, ¹¹Institute of Oncology "Prof. Dr. Alexandru Trestioreanu" Bucha, Bucharest, RO, ¹²Saitama Cancer Center, Saitama, JP, ¹³Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, FR, ¹⁴Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ¹⁵Shanghai Chest Hospital, Shanghai, CN, ¹⁶Austin Hospital, Heidelberg, AU, ¹⁷Bristol Myers Squibb, Princeton, US, ¹⁸The Ohio State University Comprehensive Cancer Center, Columbus, US

15:05 - 15:20 **Invited Discussant 960, 970, and 980**

J. Brahmer, Johns Hopkins Kimmel Cancer Center, Baltimore, US

15:20 - 15:30 **990_PR - KRYSTAL-1: Activity and Preliminary Pharmacodynamic (PD) Analysis of Adagrasib (MRTX849) in Patients (Pts) With Advanced Non-Small- Cell Lung Cancer (NSCLC) Harboring KRASG12C Mutation**

G. Riely¹, S.-H.I. Ou², I. Rybkin³, A. Spira⁴, K. Papadopoulos⁵, J. Sabari⁶, M. Johnson⁷, R. Heist⁸, L. Bazhenova⁹, M. Barve¹⁰, J. Pacheco¹¹, K. Velastegui¹², C. Cilliers¹², P. Olson¹², J. Christensen¹², T. Kheoh¹², R. Chao¹², P. Janne¹³, ¹Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US, ²University of California Irvine, Orange, US, ³Henry Ford Hospital, Detroit, US, ⁴Virginia Cancer Specialist, Fairfax, US, ⁵South Texas Accelerated Research Therapeutics (START), San Antonio, US, ⁶Perlmutter Cancer Center, New York University Langone Health, New York, US, ⁷Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, ⁸Massachusetts General Hospital, Boston, US, ⁹Moore's Cancer Center - UC San Diego Health, La Jolla, US, ¹⁰Mary Crowley Cancer Research, Dallas, US, ¹¹Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, US, ¹²Mirati Therapeutics, Inc., San Diego, US, ¹³Dana Farber Cancer Institute, Boston, US

15:30 - 15:40 **Invited Discussant 990**

A. Greystoke, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

15:40 - 15:55 **Q&A and live discussion**

A. Speakers, , CH

14:35 - 15:55 Supportive care in the era of novel therapies for thoracic cancers (EONS & IASLC NAHP Committee) Channel 2

Moderation: A. Charalambous¹, M. Ftanou², ¹ Limassol, CY, ² Melbourne, AU

14:35 - 14:50 Utilising technology to meet the unmet needs of patients with thoracic cancers

A. Charalambous, Limassol, CY

14:50 - 15:05 ctDNA monitoring for patients with EGFR mutant NSCLC: Nurse's role

R. Powell, Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB

15:05 - 15:20 Supporting the role of the caregiver across the cancer continuum

C. Degi, Babes Bolyai University, Floresti, RO

15:20 - 15:35 Nutritional Support interventions in advanced lung cancer

K. Klokoni, Limassol, CY

15:35 - 15:55 Q&A and live discussion

A. Speakers, , CH

14:35 - 15:55 Lung cancer care needs (LuCE) Channel 3

Moderation: A.-M. Baird¹, A. Comanescu², ¹St. James's Hospital, Dublin, IE, ² Bucharest, RO

14:35 - 14:50 Unmet needs in the care pathway

D. Montague, ALK Positive UK, Lightwater, GB

14:50 - 15:05 The importance of psycho-oncology

M. Rajalin, Lung Cancer Association, Stockholm, SE

15:05 - 15:20 The role of the radiotherapy in LC treatment

A. Britten, Royal Sussex County Hospital - Brighton and Sussex University Hospitals NHS Trust, Brighton, GB

15:20 - 15:35 How to implement a LC screening program out of US: Advocate perspective

S. Shilo, Israel Lung Cancer Foundation, Rehovot, IL

15:35 - 15:55 Q&A and live discussion

A. Speakers, , CH

16:10 - 17:40 AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Channel 1

Moderation: M. Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE

16:10 - 16:15 Welcome and introduction

M. Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE

16:15 - 16:30 The treatment paradigm for unresectable stage III NSCLC: Exploring the growing evidence base

M. Gottfried, Meir Medical Center, Kefar Sava, IL

16:30 - 16:45 Treating unresectable stage III NSCLC with immuno-oncology: A clinical case study

M. Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE

16:45 - 17:00 The evolving role of immuno-oncology treatment for ES-SCLC

E. Arriola, Hospital del Mar, Barcelona, ES

17:00 - 17:15 Treating 1L ES-SCLC with immuno-oncology: A clinical case study

A. Addeo, HUG, Geneva, CH

17:15 - 17:40 Live panel discussion and audience Q&A

A. Speakers, , CH



16:10 - 17:40 Bristol Myers Squibb - In-the-know with I-O: Clinical conversations and Channel considerations for thoracic cancer treatments **2**

Moderation: R. Juergens, Juravinski Cancer Center, Hamilton, CA

16:10 - 16:20 Welcome and introduction

R. Juergens, Juravinski Cancer Center, Hamilton, CA

16:20 - 16:55 Expert opinion on I-O-based treatment approaches for metastatic NSCLC

S. Peters¹, R. Juergens², ¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²Juravinski Cancer Center, Hamilton, CA

16:55 - 17:25 Discussing the evolving treatment landscape for mesothelioma

A. Tsao¹, R. Juergens², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Juravinski Cancer Center, Hamilton, CA

17:25 - 17:40 Live Q&A

A. Speakers, , CH

16:10 - 17:40	AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC	Channel 3
	Moderation: M. Perol, Léon Bérard Cancer Center, Lyon, FR	
16:10 - 16:14	Welcome and Introduction <u>M. Perol</u> , Léon Bérard Cancer Center, Lyon, FR	
16:14 - 16:24	EGFR mutation testing in patients with resectable NSCLC: Challenges and considerations <u>J. Gosney</u> , Liverpool, GB	
16:24 - 16:34	Optimising the patient journey in resectable EGFRm NSCLC: A Surgeon's point of view <u>E. Bishay</u> , Birmingham, GB	
16:34 - 16:44	Improving prognosis in patients with resected EGFRm NSCLC: A role for adjuvant EGFR-TKIs <u>M. Majem Tarruella</u> , Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, ES	
16:44 - 16:54	First-line EGFR-TKIs to improve patient outcomes in advanced EGFRm NSCLC <u>M. Perol</u> , Léon Bérard Cancer Center, Lyon, FR	
16:54 - 17:40	Audience Q&A and panel discussion <u>A. Speakers</u> , , CH	
18:00 - 19:00	Young Oncologists HowTo Session: Practical tips in managing older patients with lung cancer	Lounge
	Moderation: E. Mariamidze, Tbilisi, GE	
18:00 - 19:00	Mentor <u>F. Gomes</u> , The Christie NHS Foundation Trust, Manchester, GB	

26.03.2021

09:15 - 09:45 Heine H. Hansen Award lecture 2020 Channel 1

09:15 - 09:20 **Introduction to the Heine H. Hansen Award 2020**
T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP

09:20 - 09:45 **Biopsies, biomarkers and biology**
F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB

10:00 - 11:00 Why are there so many approaches to oligometastatic disease? Channel 1

10:00 - 10:15 **How can we define oligometastasis and how is it different from oligoprogression?**
A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

10:15 - 10:30 **Is there a role for surgery?**
P. Van Schil, University Hospital Antwerp (UZA), Edegem, BE

10:30 - 10:45 **When should I initiate, stop and resume systemic treatment?**
B. Besse, Institut Gustave Roussy, Villejuif, FR

10:45 - 11:00 **Current status of radiation therapy for oligometastasis**
F. Mcdonald, Royal Marsden Hospital NHS Foundation Trust, London, GB

10:00 - 11:00 Reasons to stop smoking and barriers preventing cessation Channel 3

10:00 - 10:15 **What are the barriers to smoking cessation and how to overcome it**
K. Gali, Stanford University, Stanford, US

10:15 - 10:30 **E cigarette and vaping: Is it a safe smoking cessation tool?**
F. Filippidis, Imperial College London-South Kensington Campus, London, GB

10:30 - 10:45 **The role of tobacco control in lung cancer care**
W. Graham, Hollings Cancer Center at the Medical University of South Carolina, Charleston, US

10:45 - 11:15 **Smoking cessation and lung cancer outcomes**
K. Berkane, Institut Gustave Roussy, Villejuif, FR

10:00 - 11:00 Thymic malignancies: New treatments Channel 2

10:00 - 10:15 **Surgery: How to improve our standard - From minimally-invasive approaches to chemo-hyperthermia**

E. Ruffini, University of Turin, Torino, IT

10:15 - 10:30 **Radiotherapy: Revisiting indication and techniques**

D. Gomez, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

10:30 - 10:45 **Ongoing systemic therapy trials: Will anything hit?**

N. Girard, Institut Curie, Paris, FR

10:45 - 11:00 **Immunotherapy: An option for now and for the future?**

J. Remon Masip, HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES

11:15 - 12:35 COVID-19 pandemic: Impact on thoracic malignancies Channel 2

Moderation: M. Garassino¹, P. Garrido Lopez², ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Hospital Universitario Ramon y Cajal, Madrid, ES

11:15 - 11:30 **How can we safely treat thoracic patients during the pandemic?**

J. Luo, Memorial Sloan Kettering Cancer Center, New York, US

11:30 - 11:45 **Intensive care and lung cancer during COVID-19 pandemic**

G. Grasselli, Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT

11:45 - 12:00 **How is pandemic affecting women careers?**

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

12:00 - 12:35 **Q&A and live discussion**

A. Speakers, , CH

11:15 - 12:35 Hitting the target in 2021 Channel 1

Moderation: N. Leighl¹, M.-J. Ahn², ¹University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²Sungkyunkwan University School of Medicine, Seoul, KR

11:15 - 11:27 **EGFR**
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

11:27 - 11:39 **Gene fusion targets**
S. Novello, San Luigi Gonzaga Hospital, University of Turin, Orbassano, IT

11:39 - 11:51 **HER2, MET, BRAF**
F. Barlesi, Gustave Roussy Cancer Campus, Villejuif, FR

11:51 - 12:03 **RAS**
N. Leighl, University Health Network - Princess Margaret Cancer Center, Toronto, CA

12:03 - 12:15 **ESCAT**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

12:15 - 12:35 **Q&A and live discussion**
A. Speakers, , CH

11:15 - 12:35 Young Oncologists Mentorship Session: Progressing your career in thoracic oncology Lounge

Moderation: J. Lim¹, M. Petrova², ¹ Manchester, GB, ²Medical Centre Nadejda Reproductive Sofia, Sofia, BG

11:15 - 11:20 **Your perspective**
B. Solomon, Sir Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, AU

11:20 - 11:25 **Your perspective**
L. Mezquita, Hospital Clinic i Provincial de Barcelona, Barcelona, ES

11:25 - 12:35 **Live discussion**

12:50 - 14:20 Janssen - Spotlight on emerging therapies for patients with EGFR-positive NSCLC Channel 1

Moderation: M.R. Garcia Campelo¹, M. Thomas², ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ²University of Heidelberg, Heidelberg, DE

12:50 - 12:55 Welcome and introductions by the Co-Chairs

M.R. Garcia Campelo¹, M. Thomas², ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ²University of Heidelberg, Heidelberg, DE

12:55 - 13:20 Reflect, adapt and aspire: A review of the NSCLC landscape, EGFR+ disease in focus

A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

13:20 - 13:45 Are we doing our best for patients with EGFR Exon 20 insertions in advanced NSCLC?

N. Girard, Institut Curie, Paris, FR

13:45 - 13:50 Key learnings and closing remarks

A. Speakers, , CH

13:50 - 14:20 Live Q&A / discussion

A. Speakers, , CH

12:50 - 14:20 Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS Channel 2

Moderation: M. Schuler, Essen, DE

12:50 - 13:10 Drugging the undruggable: The science behind targeting KRAS

M. Barbacid, CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, ES

13:10 - 13:30 Emerging KRAS-targeted therapies in NSCLC

M. Schuler, Essen, DE

13:30 - 13:50 Incorporating KRAS as a novel biomarker: Challenges and opportunities

A. Ryska, Hradec Kralove, Hradec Kralove, CZ

13:50 - 14:10 Discussion and Q&A

A. Speakers, , CH

14:10 - 14:15 Summary and close

M. Schuler, Essen, DE

14:35 - 15:05 Keynote lecture Channel 1

14:35 - 14:40 **Introduction to the Keynote lecture**

E. Felip, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

14:40 - 15:05 **Progress and future perspectives of peri-operative therapy of NSCLC**

T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP

15:20 - 16:40 I-O combinations Channel 1

Moderation: S. Peters¹, L. Paz-Ares², ¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

15:20 - 15:35 **Biological rationale for I-O combinations in solid tumours**

N. Rizvi, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

15:35 - 15:50 **Combination with chemotherapy: Current evidences and beyond**

M. Garassino, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

15:50 - 16:05 **Combination with radiotherapy: Expectations, facts and promises**

K. Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

16:05 - 16:20 **I-O/I-O combinations: Standards and new approaches including TILs**

S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

16:20 - 16:40 **Q&A and live discussion**

A. Speakers, , CH

15:20 - 16:40 Mini Oral session 1 Channel 3

Moderation: M.-J. Ahn¹, Y. Lievens², ¹Sungkyunkwan University School of Medicine, Seoul, KR, ²Ghent University Hospital, Gent, BE

15:20 - 15:25 **203MO - Changes in management for patients with lung cancer treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK (COVID-RT Lung)**

K. Banfill¹, G. Price², K. Wicks², A. Britten³, C. Carson⁴, M. Hatton⁵, K. Thippu Jayaprakash⁶, A. Jegannathen⁷, C.L. Lee⁸, N. Panakis⁹, C. Peedell¹⁰, C. Stilwell¹¹, T. Pope¹², C. Powell¹³, V. Wood¹⁴, S. Zhou¹⁵, C. Faivre-Finn¹⁶, ¹Cancer Research UK Manchester Institute, Manchester, GB, ²Manchester Cancer Research Centre, Manchester, GB, ³Royal Sussex County Hospital - Brighton and Sussex University Hospitals NHS Trust, Brighton, GB, ⁴Northern Ireland Cancer Centre, Belfast, GB, ⁵Weston Park Hospital, Sheffield, GB, ⁶Addenbrooke's Hospital - Cambridge University

Hospitals NHS Foundation Trust, Cambridge, GB, ⁷University Hospitals of North Midlands, Stoke on Trent, GB, ⁸New Cross Hospital, Wolverhampton, GB, ⁹Oxford University Hospitals, Oxford, GB, ¹⁰South Tees NHS Foundation Trust, Middlesbrough, GB, ¹¹Aberdeen, GB, ¹²The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, GB, ¹³Velindre Cancer Centre, Cardiff, GB, ¹⁴University Hospital Southampton NHS Foundation Trust, Southampton, GB, ¹⁵Beatson West of Scotland Cancer Centre, Glasgow, GB, ¹⁶The Christie NHS Foundation Trust, Manchester, GB

15:25 - 15:30 **61MO - Safety and Efficacy of Protracted Stereotactic Body Radiotherapy for Ultra-Central Lung Tumours**

J. Lodeweges, P. Van Rossum, M. Bartels, V. Brand, J. Pomp, M. Peters, J. Verhoeff, University Medical Center Utrecht, Utrecht, NL

15:30 - 15:40 **Invited Discussant 203MO and 61MO**

Y. Lievens, Ghent University Hospital, Gent, BE

15:40 - 15:45 **48MO - Phase 1 study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)**

L. Paz-Ares¹, T. Owonikoko², M. Johnson³, R. Govindan⁴, H. Izumi⁵, V. Lai⁶, H. Borghaei⁷, M. Boyer⁸, R. Boosman⁹, H.-D. Hummel¹⁰, F. Blackhall¹¹, A. Dowlati¹², Y. Zhang¹³, S. Mukherjee¹³, B. Sable¹³, A. Pati¹³, A. Shetty¹³, N. Hashemi Sadraei¹³, S. Champiat¹⁴, ¹Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES, ²Emory University School of Medicine, Atlanta, US, ³Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, ⁴Washington University Medical School, St. Louis, US, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Memorial Sloan Kettering Cancer Center, New York, US, ⁷Fox Chase Cancer Center, Philadelphia, US, ⁸Chris O'Brien Lifehouse, Camperdown, AU, ⁹The Netherlands Cancer Institute, Amsterdam, NL, ¹⁰University Hospital Würzburg, Würzburg, DE, ¹¹The Christie NHS Foundation Trust, Manchester, GB, ¹²Seidman Cancer and Case Western Reserve University, Cleveland, US, ¹³Amgen Inc., Thousand Oaks, US, ¹⁴Paris-Saclay University, Villejuif, FR

15:45 - 15:50 **49MO - Patterns of relapse following thoracic radiotherapy in patients with limited-stage small cell lung cancer as part of the CONVERT trial**

R. Portner¹, E. Vasquez Osorio², R. Iype¹, C. Faivre-Finn¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²University of Manchester, Manchester, GB

15:50 - 16:00 **Invited Discussant 48MO and 49MO**

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust; Imperial College London; Institute of Cancer Research, London, GB

16:00 - 16:05 **100MO - Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial**

S. Postel-Vinay¹, D. Planchard¹, M. Antigny¹, J. Coves Sarto², M. Domine Gomez³, R. De Las Penas Bataller⁴, M.A. Sala Gonzalez⁵, S. Viteri⁶, J. Pozas Pérez⁷, M. Texier¹, A.L. Ortega Granados⁸, M.T. Moran Bueno⁹, C.J. Camps¹⁰, A. Lopez-Martin¹¹, M. Provencio¹²,

A. Gazzah¹, J.-C. Soria¹, B. Besse¹, B. Massuti Sureda¹³, R. Rosell¹⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²Hospital Son Llatzer, Palma de Mallorca, ES, ³University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁴Hospital Provincial Castellon, Castellón, ES, ⁵Hospital de Basurto, Bilbao, ES, ⁶Dr Rosell Oncology Institute, Dexeus University Hospital, QuironSalud Group, Barcelona, ES, ⁷Hospital Universitario Ramon y Cajal, Madrid, ES, ⁸Hospital Universitario de Jaén, Jaén, ES, ⁹ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹⁰Hospital General Universitario Valencia, Valencia, ES, ¹¹Hospital Severo Ochoa, Madrid, ES, ¹²Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, ¹³Hospital General Universitario de Alicante, Alicante, ES, ¹⁴HUGTP - Hospital Universitario Germans Trias i Pujol, Badalona, ES

- 16:05 - 16:10 **101MO - Efficacy and safety of DCVAC/LuCa with chemotherapy for patients with stage IV NSCLC: A prospective, open-label, single-arm, phase 2 study**
X. Ling, J. Xu, R. Zhong, H. Zhong, B. Han, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN
- 16:10 - 16:20 **Invited Discussant 100MO and 101MO**
J. Aerts, Erasmus MC Cancer Institute, Rotterdam, NL
- 16:20 - 16:40 **Q&A and live discussion**
A. Speakers, , CH

15:20 - 16:40 Multimodality treatment in early stage Channel 2

Moderation: P.A. Thomas¹, M. White², ¹Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ²Stanford Comprehensive Cancer Institute, Stanford, US

15:20 - 15:25 **Presentation of case**

M. White, Stanford Comprehensive Cancer Institute, Stanford, US

15:25 - 15:40 **Controversies in SBRT in early stage NSCLC**

K. Franks, St. James's University Hospital Leeds, Leeds, GB

15:40 - 15:55 **Controversies in the surgical treatment of early stage NSCLC**

P.A. Thomas, Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

15:55 - 16:10 **Is there a role for I-O in the peri-operative setting for NSCLC?**

H. Wakelee, Stanford Comprehensive Cancer Institute, Stanford, US

16:10 - 16:25 **What if you diagnose an EGFR mutation at surgery?**

M. Tsuboi, Division of Thoracic Surgery and Oncology National Cancer Center Hospital East, Kashiwa, JP

16:25 - 16:40 **Q&A and live discussion**

A. Speakers, , CH

16:55 - 17:55 Brain metastases are not all the same Channel 2

16:55 - 17:10 **Surgical indications and timing**

M. De Praeter, UZA - University Hospital Antwerp, Edegem, BE

17:10 - 17:25 **State of the art and future perspective from radiation oncology**

U. Ricardi, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, IT

17:25 - 17:40 **Targeted therapy for oncogene addicted NSCLC**

J.C.-H. Yang, NTUH - National Taiwan University Hospital, Taipei City, TW

17:40 - 17:55 **Systemic treatment for non-oncogene addicted NSCLC**

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL



16:55 - 17:55 Should we use liquid biopsy? Channel 1

16:55 - 17:10 **Technical and pre-analytic issues in daily practice**

F. Lopez-Rios, HM Hospitales, Madrid, ES

17:10 - 17:25 **Molecular genotyping at diagnosis on liquid biopsies**

N. Peled, Soroka University Medical Center, Beer Sheva, IL

17:25 - 17:40 **TMB and predictive factors for ICI on liquid biopsies**

D. Gandara, University of California Davis Cancer Center, Sacramento, US

17:40 - 17:55 **Liquid biopsies at resistance on TKIs**

Z. Piotrowska, Massachusetts General Hospital, Boston, US

18:00 - 19:00 Young Oncologists Mentorship Session: Identifying and integrating research opportunities in lung cancer into your standard practice Lounge

Moderation: A.S. Berghoff, Vienna, AT

18:00 - 19:00 **Mentor**

S. Pilotto, Ospedale Borgo Roma - AOU Integrata di Verona, Verona, IT



27.03.2021

09:15 - 10:15 What is the place of the pathologist in 2021? Channel 2

09:15 - 09:30 **Will artificial intelligence (AI) make pathologists redundant?**

R. Buettner, University Hospital Cologne, Köln, DE

09:30 - 09:45 **Will liquid biopsies make histopathology redundant?**

N. Normanno, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

09:45 - 10:00 **State of the art: Use of automated tumour recognition and digital pathology**

F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

10:00 - 10:15 **Can pathologists provide the full spectrum of molecular pathology diagnostics?**

L. Bubendorf, University Hospital Basel - Institute of Pathology, Basel, CH

09:15 - 10:15 Resistance to immune checkpoint inhibitor treatment Channel 1

09:15 - 09:30 **Intrinsic resistance in relation to driver mutations**

Y. Yatabe, National Cancer Center Hospital, Tokyo, JP

09:30 - 09:45 **Intrinsic resistance in relation to TMB**

L. Bazhenova, Moores Cancer Center - UC San Diego Health, La Jolla, US

09:45 - 10:00 **Mechanisms of acquired resistance against ICI treatment: An overview**

A. Schoenfeld, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

10:00 - 10:15 **Treatment perspectives for the patients failed with ICI treatment**

L. Paz-Ares, Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES

09:15 - 10:15 YO case discussion: Challenges in clinical oncology Channel 3

Moderation: J. Corral¹, J. Lim², ¹ Madrid, ES, ² Manchester, GB

09:15 - 09:22 **Case 1: Sequence of treatment of oncogene driven NSCLC patients**

A. Lee, University College London Hospitals NHS Trust, London, GB

09:22 - 09:29 **Case 2: Immunotherapy for SCLC**

I. Gerk, St. Petersburg, RU

09:29 - 09:36 **Case 3: Treatment of metastatic NSCLC with absent PD-L1 expression and without oncogene addiction**

R. Conde, Lisbon, PT

09:36 - 09:43 **Case 4: Treatment of patients with NSCLC and brain metastases**

F. Sparano, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

09:43 - 10:15 **Case discussion**

J. Corral¹, J. Lim², A. Lee³, I. Gerk⁴, R. Conde⁵, F. Sparano⁶, ¹ Madrid, ES, ² Manchester, GB, ³University College London Hospitals NHS Trust, London, GB, ⁴ St. Petersburg, RU, ⁵ Lisbon, PT, ⁶Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

10:30 - 11:50 ESMO Colloquium co-supported by Lilly Oncology & Thermo Fisher Scientific - Targeting RET in lung cancer: State of the art in testing and therapeutics **Channel 1**

Moderation: J. Vansteenkiste¹, F. Cappuzzo², ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²Ospedale Santa Maria Delle Croci, Istituto Nazionale Tumori "Regina Elena", Rome, IT

10:30 - 10:35 Live introduction

J. Vansteenkiste¹, F. Cappuzzo², ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²Istituto Nazionale Tumori "Regina Elena", Rome, IT

10:35 - 10:50 Molecular diagnostics for detection of RET aberrations in non-small cell lung cancer: How, when and how often

F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

10:50 - 11:10 Targeting the RET fusion in patients with advanced non-small cell lung cancer: Efficacy, toxicity, quality of life and cost

O. Gautschi, Luzerner Kantonsspital, Luzern, CH

11:10 - 11:30 Two clinical cases of patients with NSCLC harbouring RET abnormalities: Critical analysis of management according to ESMO Guidelines for NSCLC and NGS use, MCBS, ESCAT

A. Passaro, European Institute of Oncology, IRCCS, Milan, IT

11:30 - 11:35 Live conclusions

F. Cappuzzo¹, J. Vansteenkiste², ¹Istituto Nazionale Tumori "Regina Elena", Rome, IT, ²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

11:35 - 11:50 Q&A and live discussion

A. Speakers, , CH

12:05 - 13:25 Optimising clinical research Channel 1

Moderation: T. Mitsudomi¹, R. Dziadziuszko², ¹Kindai University - Faculty of Medicine, Osaka, JP, ²Medical University of Gdansk, Gdansk, PL

12:05 - 12:20 **From early phase to registration in one trial: Myth or reality?**

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

12:20 - 12:35 **Exploring new drug indications: Basket and umbrella trials**

J. Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR

12:35 - 12:50 **Immunotherapy trials: Controversies and pitfalls**

M. Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE

12:50 - 13:05 **Trials involving surgery: Current landscape**

S. Hillinger, Universitätspital Zürich - Klinik für Thoraxchirurgie, Zurich, CH

13:05 - 13:25 **Q&A and live discussion**

A. Speakers, , CH

12:05 - 13:25 What's next in the management of SCLC? Channel 3

Moderation: C. Faivre-Finn¹, R.A. Stahel², ¹The Christie NHS Foundation Trust, Manchester, GB, ²University Hospital Zurich, Zurich, CH

12:05 - 12:20 **Define biomarker in SCLC**

M. Frueh, Kantonsspital St. Gallen, St. Gallen, CH

12:20 - 12:35 **Innovation in limited disease**

C. Faivre-Finn, The Christie NHS Foundation Trust, Manchester, GB

12:35 - 12:50 **Extensive disease**

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US

12:50 - 13:05 **Novel agent beyond first line**

E. Felip, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

13:05 - 13:25 **Q&A and live discussion**

A. Speakers, , CH

12:05 - 13:25 Mini Oral session 2 Channel 2

Moderation: J. Van Loon¹, J. Edwards², ¹ Maastricht, NL, ²Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

- 12:05 - 12:10 **78MO - Early safety assessment of durvalumab after sCRT in patients with Stage III, unresectable NSCLC (PACIFIC-6)**
M. Garassino¹, J. Mazieres², M. Reck³, A. Delmonte⁴, H. Bischoff⁵, R. Bernabe⁶, I.E. Díaz Pérez⁷, W. Sawyer⁸, N. Trunova⁷, C. Faivre-Finn⁹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ³Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ⁴Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ⁵Thoraxklinik Heidelberg, Heidelberg, DE, ⁶Hospital Universitario Virgen del Rocio, Seville, ES, ⁷AstraZeneca, Gaithersburg, US, ⁸AstraZeneca, Cambridge, GB, ⁹The Christie NHS Foundation Trust, Manchester, GB
- 12:10 - 12:15 **79MO - PACIFIC-R: real-world characteristics of unresectable Stage III NSCLC patients treated with durvalumab after chemoradiotherapy**
F. Mcdonald¹, F. Mornex², M. Garassino³, A. Filippi⁴, D. Christoph⁵, V. Haakensen⁶, A. Agbarya⁷, M. Van Den Heuvel⁸, P. Vercauter⁹, C. Chouaid¹⁰, E. Pichon¹¹, S. Siva¹², L. Steinbusch⁸, I. Peretz¹³, B. Solomon¹⁴, L. Decoster¹⁵, W. Sawyer¹⁶, A. Allen¹⁷, M. Licour¹⁸, N. Girard¹⁹, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Centre Hospitalier Universitaire de Lyon, Lyon, FR, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia PV, IT, ⁵Evangelische Kliniken Essen-Mitte, Evangelische Huysens-Stiftung, Essen, DE, ⁶Oslo University Hospital, Oslo, NO, ⁷Bney Zion Medical Center, Haifa, IL, ⁸The Netherlands Cancer Institute, Amsterdam, NL, ⁹Onze-Lieve-Vrouw Ziekenhuis Aalst, Aalst, BE, ¹⁰CH Intercommunal de Créteil, Créteil, FR, ¹¹CHRU de Tours, Hôpital Bretonneau, Tours, FR, ¹²Sir Peter MacCallum Cancer Centre, Melbourne, AU, ¹³Clalit Health Services, Tel Aviv, IL, ¹⁴Sir Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, AU, ¹⁵Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, BE, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸Astrazeneca, Paris, FR, ¹⁹Institut Curie, Paris, FR
- 12:15 - 12:25 **Invited Discussant 78MO and 79MO**
R. Soo, Singapore, SG
- 12:25 - 12:30 **29MO - Early-stage lung cancer detection by a noninvasive breath test**
M. Qiu¹, Z. Zhou¹, S. Meng¹, H. Li², Q. Li², J. Wang¹, ¹Peking University People's Hospital, Beijing, CN, ²Shenzhen Breatha Biological Technology Co., Ltd, Shenzhen, CN
- 12:30 - 12:35 **62MO - Comparison of lobectomy and sublobar resection for stage IA elderly NSCLC patients (≥70 years): a population-based propensity score matching's study**
B. Zhang¹, W. Liu¹, D. Ren¹, F. Li¹, Y. Wang¹, D. Huo¹, S. Zhu¹, J. Chen², Q. Song¹, S. Xu¹, ¹Tianjin Medical University General Hospital, Tianjin, CN, ²The Second Affiliated Hospital of Dalian Medical University, Dalian, CN
- 12:35 - 12:40 **63MO - Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small-cell lung cancer (NSCLC) patients - A first report of a randomized phase II trial (ASTEROID)**

A. Hallqvist¹, H. Koyi², L. De Petris³, K. Lindberg³, S. Farooqi⁴, Å. Helland⁴, A. Wikström⁵, M. Johansson⁶, M. Planck⁷, L. Lindberg⁸, Ø. Yksnøy⁹, B.H. Grønberg¹⁰, N. Helbekkmo¹¹, J. Nyman¹, ¹Dept. of Oncology, Sahlgrenska University Hospital, Göteborg, SE, ²Dept. of Pulmonary medicine, Gävle, Solna, SE, ³Thoracic Oncology Unit Karolinska University Hospital, Solna, SE, ⁴Dept. of Oncology, Oslo University Hospital, Oslo, NO, ⁵Dept. of Pulmonary medicine, Linköpings University Hospital, Linköping, SE, ⁶Dept. of Radiation Sciences, Umeå University, Umeå, SE, ⁷Dept. of Pulmonary medicine, Skåne University Hospital, Lund, SE, ⁸Dept. of Pulmonary medicine, Sunderbyn Hospital, Luleå, SE, ⁹Dept. of Pulmonary medicine, Ålesund Hospital, Ålesund, NO, ¹⁰Dept. of Oncology, St Olavs Hospital, Trondheim, NO, ¹¹Dept. of Oncology, University Hospital of North Norway, Tromsø, NO

12:40 - 12:45 **64MO - Early Experience of Bronchoscopic Transbronchial Microwave Ablation of Lung Nodules in the Hybrid Operating Room**

J. Chan, R. Lau, C. Ng, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK

12:45 - 13:05 **Invited Discussant 29MO, 62MO, 63MO and 64MO**

J. Edwards, Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

13:05 - 13:25 **Q&A and live discussion**

A. Speakers, , CH

14:00 - 15:00 Young Oncologists Mentorship Session: Combining, sequencing, optimizing chemotherapy with immunotherapy in advanced lung cancer: Trial data and real world data, how to navigate? Lounge

Moderation: C. Cardone, Naples, IT

14:00 - 15:00 **Mentor**

R. Stahel, University Hospital Zurich, Zurich, CH